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BACKGROUND Endocrine disrupting chemicals (EDCs) pose significant risks to 
public health because of their ubiquitous nature throughout the environment. Concern 
regarding these toxic substances is well-justified, with past research highlighting links to 
male, female, and even transgenerational health defects with increased exposure to these 
chemicals. Recent studies have revealed that the average American women uses 12 
personal care products (PCPs) every day, suggesting females are particularly susceptible 
to the adverse health outcomes associated with PCP-related EDC exposures (Taylor et al., 
2017).  
OBJECTIVES The purpose of this study is to characterize the role and significance of 
EDCs found in PCPs by assessing implications of exposure on female reproductive health 
outcomes. This study also seeks to explore public perceptions of PCP dangers in order to 
contextualize findings regarding body burden of chemical toxicants from different 
bioassays. 
METHODS One component of this project involves a review of publications 
highlighting the relationship between EDCs and PCPs and how successfully these 
findings have been communicated to the general public to influence their awareness of 
 vii 
the dangers of endocrine disruption (Aims 1A-1C). The second involves the creation of a 
novel PCP exposure assessment through survey analysis of pre-existing PCP surveys 
(Aim 2). The last objective centers around an analysis of bioassay-based EDC exposure 
assessments at the level of the kidney (Aim 3A) and uterus (Aim 3B) from urine and 
menstrual effluent samples, respectively. 
RESULTS A scoping review regarding the nature of the relationship between PCPs and 
EDCs was completed - yielding a total of 255 journal articles included in analysis (Aim 
1A). Urinary biomonitoring studies of EDCs populated the majority of this review, and 
measurable levels of EDCs were highest in this type of bioassay over other types of 
biological media. Published literature detailing the public’s awareness of EDCs suggests 
that people are less concerned with the health implications of repeated exposure from 
PCP usage than they are with environmental health concerns like air and water pollution 
(Aim 1B). Identification of resources available to consumers for assessment of PCP 
safety was completed successfully (Aim 1C). Tools at the public’s disposal include 
webpages, documentaries, and mobile applications. Exploration of 29 PCP questionnaires 
from outside resources facilitated the expansion of an 18-question cosmetic questionnaire 
into a 134-question PCP questionnaire to be used in future studies (Aim 2). Analysis of 
urinary biomonitoring data was unable to be completed because of legal and logistical 
setbacks in the sharing of the dataset among multiple different institutions (Aim 3A). 
Analysis of preliminary menstrual effluent biomonitoring data yielded 9,321 metabolites, 
but results from further confirmatory testing of 68 toxicants are still pending (Aim 3B). 
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CONCLUSION Taken together, the findings suggest that urinary assessments are a 
preferable method for scientists to use in bioassays to characterize relative amounts of 
EDCs within PCPs. While biomonitoring studies are valuable in conveying information 
regarding sociodemographic contributors towards heightened exposure and associated 
adverse health outcomes, a lack of awareness among the public suggests that additional 
efforts must be undertaken to stress the potential implications of these toxicants on 
environmental health – particularly in females. Continued looks at PCP usage patterns 
and EDC exposure assessments in different biological media like menstrual blood are 
important next steps for further analysis, and implementation of the expanded PCP 
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Overview of EDCs and PCPs 
The chemical company DuPont’s popular advertising slogan, “Better living 
through chemistry” was first used by American marketers in 1935 as a tactic to restore 
the public’s confidence in big businesses and corporations responsible for producing and 
selling material products (Shanken 2006). By highlighting the supposed safety of 
chemicals contained in consumer goods, companies sought to change opinions about the 
tendency of large greedy corporations to ignore societal health concerns in the name of 
profit and worked to foster a newfound sense of trust between producers and consumers. 
A few decades later, however, a shift in perspectives would emerge. Chemical agents 
began being researched in greater depth to understand the human health impacts 
associated with exposure. One chemical of concern was perfluorooctanoic acid (PFOA), 
which was found in Teflon, a plastic material paradoxically produced by DuPont — the 
originators of the “better living through chemistry movement” themselves (Darrow et al., 
2016). 
The name “endocrine disrupting chemical” (EDC) refers to any exogenous 
toxicant that can interfere with the physiological functioning of the body’s endocrine 
system. EDCs, which work by mimicking the body’s hormonal system, include both 
natural and synthetic classes of chemical compounds such as bisphenols, phthalates, 
benzophenones, antimicrobials, polychlorinated biphenyls (PCBs), and parabens (Cho et 
al., 2020). While the term “endocrine disruptor” was formally established in 1991 at a 
meeting of scientists gathered to discuss the detrimental effects of chemicals on 
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environmental health, initial attention regarding potential chemical exposure risks began 
as early as the year 1962 with the publication of the novel Silent Spring by American 
biologist Rachel Carson (Epstein 2014). Carson’s novel highlighted the threat to public 
health that had come from the agriculture industry’s use of pesticides such as the 
endocrine disruptor dichlorodiphenyltrichloroethane (DDT), and her concerns regarding 
widespread effects of chemical toxicity have been echoed by scientists worldwide ever 
since the book’s release. Journal publications throughout the 1990s detailed some of the 
earliest research studies responsible for changing society’s perceptions of the dangers of 
EDCs, with papers linking pesticide exposure to health complications such as breast 
cancer and infertility in women (Hunter & Kelsey, 1993; Smith et al., 1997). The release 
of Theo Colborn’s book Our Stolen Future, Are We Threatening Our Fertility, 
Intelligence and Survival?—A Scientific Detective Story in 1996 further heightened 
concerns about chemical toxicity within the general public by discussing the negative 
repercussions of EDCs on prenatal development. 
While larger-scale environmental exposures to EDCs still remain paramount 
topics for research and discussion in current times, a noticeable interest in the chemicals 
found within individual skincare, haircare, and cosmetic products has emerged in recent 
years. In 2017-2018 alone, the natural skincare market grew to 1.6 billion dollars, 
suggesting the influence of the so-called “sustainable beauty movement” on the consumer 
and how these beliefs have led to a prioritization of certain products and ingredients over 
others (Rubin & Brod, 2019). The “personal care products” (PCPs) spoken of refer to any 
manufactured products that are used regularly by consumers for hygiene and grooming 
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purposes. Because endocrine disruptors can persist in plasticizers used to bottle and 
package these PCPs during the production process and can even be present in the 
formulas of the products themselves, studies on EDC exposure from PCPs are of specific 
interest for public health assessments (Dutta et al., 2020). The frequency and duration of 
application and usage of products containing harmful chemicals in turn may increase 
concern for exposure associated health risks.  
While these concerns have pressured manufacturers to modify the formulas for 
their products or at the very least - to explicitly label the chemicals they contain - the U.S. 
Food and Drug Administration (FDA) still does not require approval before beauty 
products go to market (Bergfeld et al., 2005). Because beauty/personal care products are 
so often exempt from the same stringent guidelines that food products and 
pharmaceutical drugs face before being available for public usage and consumption, 
PCPs are of primary significance for a research project on endocrine disruption 
(Bergfeld). Without governmental and regulatory oversight over the production and 
selling of these products, the public will continue to utilize potentially hazardous PCPs in 
their daily routines - often without the knowledge of how much danger these products are 
to their health and wellbeing. In turn, increased chemical burden will continue to 
manifest in the host of EDC-associated diseases and disorders throughout the population. 
The healthcare system as a whole will continue to bear the cost of treating or managing 
problems that could have been avoided early on through simple, actionable steps taken by 
consumers to substitute any PCPs of concern for safer alternatives.  
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With these repercussions in mind, the overarching goal of this thesis is to use 
literature and lab-based research methods to better characterize the nature and 
significance of EDC exposure from PCPs within field of public health. One specific 
objective undertaken to execute this goal involves conducting a literature review of 
publications highlighting the EDC/PCP relationship and how successfully these findings 
have been communicated to the general public to influence their awareness and 
perception of the dangers of endocrine disruption due to PCPs (Aim 1). This thesis will 
also involve designing a novel PCP exposure assessment through survey analysis of pre-
existing PCP surveys (Aim 2) and analyzing bioassay-based EDC exposure assessments 
at the level of the kidneys from urine samples (Aim 3A) and at the level of the uterus 
from menstrual blood samples (Aim 3B).  
 




Before touching on the specific methodology of these objectives, however, the 
remaining subsections of this introduction will first help to contextualize the significance 
of PCPs in relation to EDCs by provide background information on where EDCs are 
found, how they work, and how one’s susceptibility to these chemicals can be heightened 
or lessened by genetic, situational, or environmental factors. 
Sources of Exposure 
Endocrine disruptor exposure is widespread throughout the population, as EDCs 
persist in four major categories that humans constantly come in contact with: the 
environment, food sources, manufactured products (e.g., household items, pharmaceutical 
products), and PCPs (Tijani et al., 2016). Subjection to these toxic environmental agents 
can also be heightened in certain professions like hairdressing, painting, farming, and 
cleaning, as these workplaces involve probable contact with substances containing 
endocrine disruptors, so certain populations are more at risk (Van Tongeren et al., 2002).  
Within these four general categories, EDCs can be associated with natural or 
man-made sources. Natural exposures to these toxicants are typically associated with 
food products containing phytoestrogens, which are plant compounds with estrogen-like 
effects, and with water from wastewater treatment plants that contain nonyl phenol 
ethoxylates (NPEs), a class of detergent-like compounds (Beszterda et al., 2018; Nasu et 
al., 2001). Exposures from synthetic toxicants are also well characterized in the field of 
endocrine disruption, with food and beverage products and plastic/packaging materials 
serving as primary vehicles of exposure (Martina et al., 2012).  
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There are several examples of EDC exposure within PCPs containing these 
synthetic toxicants in their formulas or packaging materials (Figure 2). For one, the 
antibacterial agent triclosan (TCS) is associated with the use of consumer products such 
as deodorant, toothpaste, soap, and hand sanitizer (Allmyr et al., 2006). Benzophenone-3 
(BP-3) is an EDC found in most sunscreen formulas (Krause et al., 2012). Phthalates and 
phthalate esters are usually present in perfumes and fragrances (Huang et al., 2018). The 
preservative formaldehyde has also been detected in shampoo and hair dye products 
(Flyvholm et al. (a-b), 1993).  
 
Figure 2. Venn Diagram of EDC/PCP Relationship. 
 
Heavy metals such as mercury are a common chemical impurity in skin creams, 
and lipsticks have been found to contain the metals lead, chromium, and nickel in many 
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toxicology studies (Travasso 2014; Al-Saleh et al., 2009). Individual guidelines on heavy 
metal content in PCPs vary by country, but the United States (US) and Canada have 
enacted similar limits for their use in cosmetics. Maximum heavy metal concentrations 
within cosmetics are explicitly outlined according to Canadian public health guidelines, 
with a maximum allowable concentration of 10 parts per million (ppm) for lead, 3 ppm 
for mercury, and 3 ppm for cadmium (Borowska & Brzoska, 2015). While the FDA does 
not currently set a limit for total lead content for lipstick in the US, they have imposed a 
limit of 10-20 ppm for lead content ranges deemed safe for use as color additives in 
cosmetics like eye shadow (Al-Saleh).  
The Agency for Toxic Substances and Disease Registry (ATSDR) assigns 
chemicals Minimal Risk Levels (MRLs), which are specific estimates of one’s exposure 
to a particular hazardous substance that will not cause an appreciable risk of adverse 
noncancer health effects over a specified time duration, but these screening tools are only 
available in regard to oral and inhalation routes of exposure (Chou & Williams-Johnson, 
1998; US Department of Health and Human Services, 2018). Exposure to toxicants via 
the dermal route is most common method of PCP application, so a lack of MRLs derived 
for the dermal route of exposure makes risk assessments of chemical exposure from PCP 
usage challenging (Gosens et al., 2014; US Department of Health and Human Services, 
2018). Thus, the harmful implications associated with endocrine disruptors make them an 
important topic of study for the field of environmental health. 
EDC Mechanisms of Action 
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In addition to their pervasive nature, endocrine disruptors pose risks to the public 
because they are capable of working through different mechanisms. These toxicants can 
evade the body’s protective immunological pathways for destruction due to their short 
half-lives. In a small window of time, they are capable of increasing and decreasing 
hormone levels in the bloodstream, altering the body’s sensitivity to different hormones, 
and interfering with the process of steroidogenesis so that the body can no longer produce 
necessary levels of corticosteroids and sex steroids (Combarnous & Nguyen, 2019). By 
binding antagonistically to receptors, EDCs are able to mechanistically block natural 
hormones from doing their job of carrying out necessary metabolic functions. Disruptions 
in metabolism in turn will affect normal bodily homeostasis, dysregulating 
developmental processes and potentially leading to deleterious health effects for men, 
women, and children in the future (Kabir et al., 2015).  
Significance: Adverse Health Effects 
 Knowledge of the sources of EDCs and their mechanistic capabilities leads to the 
inevitable question of what implications repeated exposure to these chemicals can have 
on human health. Phthalates are one example of an EDC class that have been associated 
with reproductive health disorders such as endometriosis and infertility in women in 
certain case-control studies and literature reviews (Kim, 2015; Rattan, 2017). Studies 
have also elucidated a link between female gynecological disorders such as polycystic 
ovary syndrome (PCOS) and uterine fibroids with increased exposure to EDCs such as 
bisphenol A (BPA) (Cho et al., 2020). Significant correlations between increased EDC 
exposure and various cancers have been found in prospective studies for both men and 
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women, including that of the skin (Zhang et al., 2020), bladder (Gago-Dominguez et al., 
2001; Andrew et al., 2004; Koutros et al., 2011), breast (Eberle et al. 2020; Heikkinen et 
al. 2015), and ovaries (Zhang et al., 2020).  
Support for these associations through past research cannot be considered direct 
evidence of causation, however, as results from other studies evaluating the same links 
have been inconclusive and/or unable to demonstrate the same findings. Lang et al. 
(2008), a retrospective study looking at urinary BPA levels and risk of breast cancer 
among Americans throughout the years 2003-2004, did not find any significant 
associations between increased BPA exposure and elevated breast cancer risk among 
study participants (Lang et al., 2008). The odds ratio in this study was 1.12 (95% 
confidence interval [CI]: 0.85, 1.48), indicating that there was a 12% increase in the odds 
of a breast cancer diagnosis given increased exposure compared to with normal urinary 
BPA levels (Lang). 
Significance: Transgenerational Effects 
Continued contact with EDCs has proven to be harmful to the health of men and 
women, but these chemical exposures can also contribute to developmental delays in 
subsequent generations. EDC effects can be passed down from mother to child when the 
fetus is exposed to EDCs prenatally during gestational development. A longitudinal study 
by Harley et al. (2019) measured urinary biomarkers of mothers during pregnancy and of 
their sons and daughters at the age of 9 and used milestones such as thelarche, 
gonadarche, pubarche, and menarche to distinguish how timing of pubertal onset in 
children from the study would be affected by differences in maternal exposure to 
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phthalates, parabens, and phenols during pregnancy (Harley et al., 2019). In this study, 
pubarche was defined by the age at which girls and boys reached the second stage of 
pubic hair development according to the Clinical Tanner staging scale, with girls having a 
median age of 10.3 years and boys having a median age of 12.2 years (Harley). 
Statistically significant findings from the study indicated that girls had a mean shift of -
1.3 months for pubarche with a twofold increase in prenatal urinary methyl paraben (MP) 
concentration, as well as mean shifts of -0.7 and -0.8 associated with doubling of prenatal 
urinary TCS and 2,4-dichlorophenol (2,4-DCP), respectively - suggesting that maternal 
increases in concentrations of certain EDCs may lead to earlier onset of both pubic hair 
development and menstruation in girls (Harley). While doublings of prenatal 
concentrations of MP, TCS, and 2,4-DCP were associated with mean shifts of -0.5, -0.4, 
and -0.9 months, respectively for boys, these results were not found to be statistically 
significant (Harley).  
The deleterious effects of maternal exposure to EDCs can also be observed 
postnatally when a child consumes breast milk containing traces of these chemicals. A 
longitudinal study by Tai et al. (2016) in Vietnam found that higher perinatal exposure to 
the EDC 2,3,7,8-tetrachlorodibenzo-p-dioxin (2,3,7,8-TetraCDD) during breastfeeding 
was associated with both cognitive and developmental deficits in boys and with 
developmental deficits in girls (Tai et al., 2016). Children were classified in the “high 
exposure” to 2,3,7,8-tetrachlorodibenzo-p-dioxin (2,3,7,8-TetraCDD) group based on 
levels of this EDC in their mothers’ breast milk (Tai). Measurements of body size 
(including abdominal circumference, weight, height, etc.) were taken, and the Bayley 
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Scales of Infant and Toddler Development Third Edition (Bayley-III) test was 
administered at different stages of development to assess neurodevelopmental effects 
over time (Tai). High 2,3,7,8-TetraCDD exposure was associated with decreased 
composite motor and gross skills for boys, as estimated marginal mean Bayley-III 
composite and gross motor scores were 100.1 (95% CI: 96.4, 103.8) and 9.9 (95% CI: 
9.0, 10.8), respectively (Tai). High 2,3,7,8-TetraCDD exposure was also associated with 
increases in all of the body size measurements taken for boys (Tai). High 2,3,7,8-
TetraCDD exposure was associated with increases in some of the body size 
measurements for girls in the same study. Increases in estimated marginal means for head 
and abdominal circumferences at birth were 0.18 cm (95% CI: -0.08, 0.44) and 0.01 cm 
(95% CI: -0.23, 0.25), respectively for these girls (Tai). No decreases in cognitive deficits 
were observed in girls with high exposure to 2,3,7,8-TetraCDD exposure, however (Tai). 
Epidemiology of EDC/PCP Exposures 
Associations between increased PCP usage and increased body burden noted by 
elevated blood/urine concentrations of endocrine disruptors is a finding well-supported 
by the scientific literature published in recent years. A 2018-2019 Spanish case-control 
study on endometriosis is one example of this trend, as study participants who reported 
weekly application of face masks had statistically significant (p<0.05) differences in 
urinary concentrations of BP-3 and its derivative, benzophenone-1 (BP-1), compared to 
those who applied face masks less frequently than once per week (Peinado et al., 2020). 
The same study also showed that the usage of facial creams more than 1 time/day was 
associated with statistically significant elevations in urinary concentrations of another 
12 
BP-3 derivative, 4-OH BP (Peinado). This pattern of increased exposure with more 
frequent PCP usage wasn’t just limited to benzophenone and its derivatives, as elevations 
in urinary MP and ethyl paraben (EP) concentrations were also observed to the same 
level of significance for participants who reported daily usage of facial cream and usage 
of lipstick more than 1 time/day, respectively (Peinado).  
In the US, Ferguson et al. (2017) conducted a cross-sectional study that used 
National Health and Nutrition Examination Survey (NHANES) data to explore 
associations between PCP usage and urinary concentrations of endocrine disruptors 
(Ferguson et al., 2017). NHANES is a population-based biomonitoring study that has 
been run by the National Center for Health Statistics, a branch of the Centers for Disease 
Control and Prevention (CDC), since the 1960s and seeks to characterize the health and 
nutritional status of the American population through questionnaire administration, 
physical exams, and laboratory testing of participants. The Ferguson study analyzed 
NHANES data from adult participants in the 2009-2010 and 2011-2012 cycles, and 
results from this study indicated that respondents who reported “always” in regards to 
their mouthwash or sunscreen usage had higher significantly higher urinary metabolite 
levels of MP and BP-3 compared to those who reported never having used mouthwash or 
sunscreen (Ferguson).  
Results from a biomonitoring study done in Korea further demonstrate how 
connections between product usage frequency and EDC exposure can contribute to 
overall body burden of certain toxicants (Park et al., 2019). Researchers from this 
particular study found that usage of haircare products, body cleansers, and cosmetic 
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products more than once per week were all associated with significantly higher odds 
ratios (1.20, 1.28, and 1.33 respectively) for TCS exposure in female participants 
compared to their counterparts who were infrequent users of these 3 types of PCPs (Park 
et al., 2019). 
Considering that certain populations have heightened risks of exposure, 
knowledge regarding EDC exposure is pertinent when one considers how these 
sociodemographic factors can lead to significant health implications when compounded 
with additional risk factors like frequent PCP usage. One variable studied extensively 
with regard to endocrine disruptor exposure is age, with a general trend indicating 
increasing levels of these compounds present in the body as one ages. An Iranian cross-
sectional study looked at sociodemographic and lifestyle indicators of MP, EP, propyl 
paraben (PP), and butyl paraben (BP) urinary concentrations and found a significant 
positive association between urinary MP levels and age groups, with study participants 
between the ages of 12-16 having a mean MP concentration of 112.59 µg/L and 
participants ages 17-20 having a mean MP concentration of 260.84 µg/L (Kiani Feizabadi 
et al., 2020). A US study also found positive correlations between age and paraben 
concentrations, with analysis of NHANES data from urine samples in 2005-2006 
revealing how older respondents had significantly higher levels of parabens compared to 
younger respondents (Calafat et al., 2010). A third study using NHANES data from 2007-
2008 provides additional support for the pattern of age-related EDC prevalence in other 
chemical classes as well. Analysis of the data from that particular study highlights 
significant positive associations between age and urinary TCS levels, in addition to 
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expected significant positive associations between age and EP and BP concentrations 
(Koeppe et al., 2013). 
         Race/ethnicity is another factor that can play a role in EDC exposures and 
associated adverse health effects. Results from a longitudinal study examining TCS and 
paraben exposure and related risk of allergic diseases showed how maternal plasma 
concentrations of MP, PP, and TCS differed significantly between maternal race/ethnicity 
groups across the US (Lee-Sarwar et al., 2018). In this study, mean plasma 
concentrations of MP were the highest of all EDCs for all races/ethnicities, with specific 
breakdowns of this EDC as follows: 15.1 ng/mL (95% CI: 7.1, 25.0) for black, non-
Hispanic participants, 10.2 ng/mL (95% CI: 5.2, 22.2) for Hispanic participants, 7.2 
ng/mL (95% CI: 3.2, 15.3) for White, non-Hispanic participants, and 24.2 ng/mL (95% 
CI: 7.3, 46.7) for participants of other races/ethnicities. For PP, black, non-Hispanic 
participants had mean plasma concentrations of 2.6 ng/mL (95% CI: 1.0, 5.3), Hispanic 
participants had mean plasma concentrations of 1.7 ng/mL (95% CI: 0.6, 4.3), White, 
non-Hispanic participants had mean plasma concentrations of 1.2 ng/mL (95% CI: 0.5, 
2.7), and participants of other races/ethnicities had mean plasma concentrations of 4.1 
ng/mL (95% CI: 1.3, 7.3). For TCS, black, non-Hispanic participants had mean plasma 
concentrations of 1.7 ng/mL (95% CI: 1.0, 3.4), Hispanic participants had mean plasma 
concentrations of 2.8 ng/mL (95% CI: 1.2, 9.5), White, non-Hispanic participants had 
mean plasma concentrations of 2.8 ng/mL (95% CI: 1.5, 8.7), and participants of other 
races/ethnicities had mean plasma concentrations of 3.8 ng/mL (95% CI: 1.9, 7.9). 
Another longitudinal study’s findings regarding maternal-child pairs in the US revealed 
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that urinary TCS levels during pregnancy were 41% (95% C: -55, -22) lower for black 
women compared to white women, and the same pattern of race-related differences was 
observed in the subsequent EDC measurements from the children of these women (Stacy 
et al., 2017). A third study that used NHANES data to look at trends in urinary BPA 
levels and body composition of American children revealed statistically significant 
differences in mean urinary BPA levels among children of different races, with Mexican 
American children having the lowest levels at 4.09 ng/mL (standard error [SE]: 0.33) 
(Li). Mean urinary BPA levels were 5.40 ng/mL (SE: 0.33), 6.23 ng/mL (SE: 0.42), 7.11 
ng/mL (SE: 2.69), and 8.00 ng/mL (SE: 2.19) for non-Hispanic white, non-Hispanic 
black, other Hispanic, and other children, respectively (Li et al., 2017).  
Detailed analyses into relationships between SES and exposure outcomes have 
been done throughout the world, but income-related patterns of susceptibility are not 
consistent among all classes of endocrine disruptors. A US study demonstrated a positive 
EDC/SES relationship by showing that higher urinary BP-3 and TCS levels significantly 
correlated with higher household income in a cohort of women from Colorado (Polinski 
et al., 2018). Specific results from this study indicated that women who had a yearly 
annual income of $40,000 or below had geometric means (GMs) of 8.3 nmol TCS/g 
creatinine (95% CI: 5.6, 12.3) and 70.4 nmol BP-3/g creatinine (95% CI: 51.4, 96.6), 
while those who earned more than $40,000 per year had GMs of 27.3 nmol TCS/g 
creatinine (95% CI: 21.7,34.2) and 220.1 nmol BP-3/g creatinine (95% CI: 177.7, 272.6) 
(Polinski). Negative correlations between SES and EDCs have been observed for other 
chemicals like phthalates, however, as a different Korean study suggested urinary 
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phthalate levels tend to be higher among subjects with a lower income (Lee et al., 2017). 
This inverse relationship was seen again in a US study that showed how individuals from 
families with an income of less than $1,500/month had significantly higher (p<0.05) 
urinary concentrations of butyl benzyl phthalate (BBP) than the mean estimated exposure 
of 0.84 µg/kg/day. The same individuals also had significantly higher (p<0.05) urinary 
concentrations of di (2-ethylhexyl) phthalate (DEHP) than the mean estimated exposure 
of 0.41 µg/kg/day (Koo et al., 2002).  
As was discussed earlier in the introduction, another risk factor for endocrine 
disruption can be occupation. One example of this relationship can be seen in a Chinese 
case-control study that looked at urinary concentrations of eight phthalate metabolites 
between occupationally exposed and non-exposed groups. Researchers in the study found 
that waste plastic recycling site workers had higher urinary levels of monobenzyl 
phthalate (MBzP), mono (2-ethyl-5-hydroxylhexyl) phthalate (MEHHP), and mono-n-
octyl phthalate (MOP) compared to their age-matched counterparts working in fields 
without exposure risks (Wang et al., 2018). Work related exposures have been assessed in 
a study of the U.S. population, where researchers found that (DEHP and di-n-butyl 
phthalate (DBP) levels for both workers in polyvinyl chloride (PVC) manufacturing 
industries and workers in nail salons significantly exceeded those of the general 
population (Hines et al., 2009). Job-related heightened exposures towards phthalates have 
been found in the hairdressing industry as well (Kolena et al., 2017).  
Data linking exposure variances to EDCs with geography alone is somewhat 
scarce due to the different factors within a geographical region (climate/season, 
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population size, racial diversity, etc.) that are employed more frequently in studies to 
account for distributional differences. However, a paper written regarding differences in 
exposure due to sampling locations alone used NHANES data to show that the GM of 
urinary BPA was 1.44 μg/L for study participants residing in rural areas, while urban 
residents had a lower GM of 1.27 μg/L of BPA detected (Calafat et al., 2005). A 2009 
cross-sectional study taking place in Korea similarly found that place of residence was an 
important marker in influencing exposure outcomes for EDCs, as respondents from rural 
locations had significantly higher urinary concentrations of the toxicant BPA than did 
respondents from urban areas (Kim et al., 2011). The Endometriosis, Natural History, and 
Diagnosis (ENDO) study from 2007-2009 highlighted statewide differences in EDC 
exposure to 5 BP-3 metabolites (Kunisue et al., 2012). Specific results from this study 
indicated how the median urinary concentration was 24 ng/mL (95% CI: 3.4, 100) for 2-
hydroxy-4-methoxybenzophenone (2OH-4MeO-BP) and 0.42 ng/mL (95% CI: 0.23, 
0.73) for 4-hydroxybenzophenone (4OH-BP) in participants from California. For 
participants from Utah, however, the median urinary concentrations for 2OH-4MeO-BP 
and 4OH-BP were lower at 5.3 ng/mL (95% CI: 1.9, 28) and 0.35 ng/mL (95% CI: 0.17, 
0.68), respectively. The conclusions from these three studies serve as examples of how 
differences due to geographical area can indeed account for differences in EDC exposure 
across a population. 
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SPECIFIC AIMS 1A-1C 
Aim 1: Identification of existing scientific literature regarding PCP/EDC 
relationship and evaluation of public perception of PCP dangers and associated 
resources to increase general awareness with the population. 
The first component of this thesis involves conducting a comprehensive literature 
review of studies linking endocrine disruptors to PCPs. This analysis will yield insight 
into contributors towards heightened EDC exposure as well as the specific health 
conditions that are associated with these particular sources of exposure. The literature 
review will also involve assessment of bioassays done by researchers to measure 
exposure within the population. Once a thorough compilation of literature had been 
completed, the journal articles were categorized into three subcategories: 1) articles that 
described sources of exposure to EDCs and detection limits in different bioassays, 2) 
articles that explored risk associations towards adverse health effects due to EDC 
exposure, and 3) articles that highlighted demographic and lifestyle factors that might 
account for possible exposure associations with EDCs. 
This analysis of journal articles linking EDCs with PCPs (Aim 1A) will involve 
exploring the field of endocrine disruption through the lens of the general public as well. 
Papers highlighting public knowledge and perception of toxic chemicals into products 
commonly used are of specific interest for this aspect of the thesis, as they will provide 
insight into a layman’s perception of awareness and exposures (Aim 1B). Alongside the 
review of the literature of public perceptions of environmental health, the identification 
of resources (e.g., websites, smartphone applications, etc.) guiding environmental health 
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decisions will be conducted (Aim 1C).  The publicly available tools advertised to help 
people make decisions to purchase and consume products that could heighten or lessen 
their susceptibility to health problems for themselves and their children will be evaluated 
and summarized. By gauging consumers’ knowledge and awareness of the dangers of 
these EDCs, insight into purchasing preferences and behavioral patterns that might 
influence exposure risks will be made possible.  
METHODS AIMS 1A-1C 
Aim 1A 
Scoping literature searches were performed via the electronic databases PubMed 
and Google Scholar. Journal articles pertaining to the total number of EDC bioassays 
were identified through searches with keywords and phrases such as “personal care 
products,” “endocrine disruptors,” “endocrine disrupting chemicals,” and “toxic 
cosmetics.” Articles that were included in this literature review were limited to those 
published on or after the year 1991, when the term “endocrine disruptor” was first 
distinguished. The PDFs of these articles were reviewed and saved, and their PubMed 
Reference Numbers (PMIDs) were taken from PubMed and documented on the software 
program Zotero to keep track of references. Relevant publications were then summarized 
on an Excel spreadsheet with key features like year of publication, type of study 





Table 1: Comprehensive EDC/PCP Literature Searches. 
PMID Author(s) Title Year Paper Summary Disorder 
Type of 
Study EDC(s) studied 
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To investigate the general public’s response to these findings, studies detailing the 
general public’s typical PCP usage and purchasing patterns, as well as their overall 
knowledge and awareness of the dangers of EDCs found within PCPs, became of interest 
for the second aim of this thesis. Specific journal articles were identified by PubMed 
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searches- this time by using keywords such as “awareness,” “perception,” “personal care 
product,” and “chemical dangers,” and articles selected for inclusion in the analysis were 
again limited to those published on or after the established 1991 cutoff date.  
Aim 1C 
Media sources available to the public, including webpages, documentaries, and 
smartphone applications, were investigated through internet searches to get a sense of 
their familiarity within the general public. Specific indicators of popularity for mobile 
applications were determined by quantitative data such as the number of reviews and 
average rating on both the Apple App Store for iPhone users and the Google Play store 
for Android users. The year of development was also noted for each of the applications to 
get a sense of the general timeframe associated with the push for increased awareness of 
chemical toxicants in PCPs. 
RESULTS AIMS 1A-1C 
Aim 1A 
A total of 255 articles were recorded on an Excel document for the initial 
literature review in the EDC/PCP relationship. 176 of the included articles involved 
different types of bioassays that have been done on EDCs since the year 1995, with the 
urine being the most commonly sampled biological media and the menstrual blood being 
represented the least in these research studies (Figure 3).  
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Figure 3. Papers Highlighting Bioassays Completed to Assess EDC Exposure. 
 
By demonstrating that while the total amount of each metabolite may differ 
between biological media, the relative concentrations of each remain the same, Zhang et 
al.’s (2020) article provides a critical overview of what most biomonitoring studies 
actually found (Zhang et al., 2020).  For example, this particular study involved the 
measurement of parabens in peripheral and menstrual blood of a cohort of Chinese 
university students (Zhang). Results from the study showed that MP was accounted for in 
68% of urine samples and 52% of blood samples. 
Furthermore, 20 of the articles identified from this literature review explored 
specific associations between hair product usage and endocrine disruption, and journal 
articles detailing exposures to endocrine disruptors from cosmetics, skincare, and 


























A total of 2 journal articles, one from Chan et al. and the other from Hartmann & 
Klaschka, were identified through literature searches of studies highlighting general 
public PCP usage, risk assessments, and overall perceptions of environmental health and 
safety across the world.  
Chan’s 2015 study - which employed survey methods to look at U.S. female 
college students’ awareness of environmental health toxins - speaks to the pervasive 
nature of PCP usage in everyday life, as 69% of respondents reported using 11 
products/day and 56% using 12+ products/day (Chan et al., 2015). Another relevant 
finding from Chan’s study reveals that while 77% of respondents in the study attributed 
environmental health concerns to air pollution and 26% recognized water contamination 
as being a contributor, only 3% of respondents mentioned PCPs as being a cause of 
concern as well (Chan). Furthermore, the study demonstrates a divide in opinions 
regarding chemical safety, as 42% of respondents thought using cosmetics were safe, 
whereas 48.6% responded that they were uncertain (Chan). 
The other study - Hartmann & Klaschka’s paper - provides insight into 
consumers’ chemical risk perception through an online survey regarding harmful 
substances in consumer products (Hartman & Klaschka, 2017). One of this study’s 
finding indicates a belief amongst the public that avoidance is the best strategy for risk 
reduction, as 74.6% of respondents shared that they would not purchase products with 
harmful substances to mitigate their personal risk. The study also detailed how the 
majority of people pay attention to the labeling and packing of products when selecting 
which ones they deem to be safe for use, with 86.2% of respondents indicating hazard 
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pictograms and 76% indicating ingredient lists as being primary sources for obtaining 
information regarding product safety (Hartmann & Klaschka).  
Aim 1C 
Resources dedicated to the awareness and dangers of endocrine disruptors were 
found to encompass a variety of platforms, likely due to the surge of the “clean beauty 
movement” made popular by marketers over the last decade (Rubin & Brod). Two 
popular web pages dedicated to these efforts have been created by the Environmental 
Working Group (EWG) and the nonprofit organization Made With Safe Ingredients 
(MADE SAFE). EWG’s Skin Deep online cosmetics database allows consumers to 
search for PCPs of interest, and the site will generate a safety ranking based on an 
assessment of the product’s ingredient list. MADE SAFE offers an online list of products 
free of carcinogens, endocrine disruptors, neurotoxins, and other harmful substances, 
making it easy for consumers to use as a guide when selecting safe products. The short 
films Story of Cosmetics (2010) and Reefs at Risk (2017) raise awareness about the 
dangerous agents contained in cosmetics and sunscreen products and the implications 
these chemicals have on the health of humans and the larger ecosystem as a whole, and 
the full-length documentary Toxic Beauty (2019) is available on popular streaming 
platforms like Hulu, Amazon Prime, and YouTube for people to learn more about this 
topic. On the Apple App Store and Google Play Store, consumers with smartphone 
devices can refer to the following applications as resources: Think Dirty, EWG Healthy 
Living, Detox Me, CosmEthics, and Chemical Maze (Table 2).  
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Table 2: Evaluation of Popularity of Mobile Applications Used in Assessment of 

































2017 >120,000 533 3.3/5 6,372 2.4/5 
Detox Me 2016 N/A 98 4.3/5 203 4.3/5 
CosmEthics 2014 >140,000 1 5/5 424 3.2/5 
Chemical 
Maze 
2010 >1,200 3 5/5 100 4.5/5 
 
DISCUSSION AIMS 1A-1C 
Aim 1A 
Analysis of the bar graph (Figure 3) suggests that urine bioassays are the most 
prevalent type of EDC biomonitoring study conducted from articles included in the 
literature review. This finding regarding the predominance of urinary EDC assessments is 
unsurprising, as quantifications of EDCs with short half-lives (e.g., phthalates) of <24 
hours are more successful when done using urine samples (Braun et al., 2016). Because 
phthalates do not accumulate in the body and are instead rapidly metabolized to 
monoesters, it is preferable to conduct urine bioassays when measuring for relative 
amounts of phthalates within the body (Braun). Similarly, BPA is another EDC that can 
be quantified at higher levels and with less contamination in the urine, making it a 
suitable assay for a biomonitoring study (Faniband et al., 2014). Screening of toxicants 
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with longer half-lives (e.g., perfluoroalkyl substances (PFASs)) of up to 7.3 years can be 
done successfully through a single blood or urine sample, but most EDCs are 
characterized by their short half-lives (Braun).  
Another key takeaway from this literature review is that greater EDC 
concentrations can be measured in certain biological media (e.g., urine) over others, but 
each bioassay type still demonstrates the same relative differences in overall EDC 
exposure (e.g., if MP was the EDC found at the highest concentration in urine, it would 
still be found in the blood at the highest concentration compared to the other EDCs 
detected in the blood). These differences in concentrations can be explained by the fact 
that blood samples often yield lower amounts of EDCs due to the impact of exogenous 
contamination during the storage and processing of these biospecimens at the laboratory 
(Braun).  
Aim 1B 
The suggestion from Chan’s study that people are generally more concerned with 
health risks associated with global environmental issues (including water and air 
pollution) over PCP risks is not surprising, as this finding held true in two other studies 
evaluating public perspectives on detriments to overall health. Participants from a study 
highlighting perceptions of environmental health risks in the American Indian and Alaska 
Native populations named arsenic-containing drinking water and air pollution exposures 
as the two primary areas of concern in regard to health risks such as associated 
respiratory diseases, which is consistent with the suggestion in the Chan paper that 
ecological health issues are at the forefront of people’s concerns (Mayer et al., 2019). 
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Similarly, respondents in a study assessing public awareness of the microplastics found in 
facial cleansers all reported believing that the facial cleansers they use were safe- despite 
studied health defects associated with microplastics (Anderson et al., 2016; Campanale et 
al., 2020). This too is consistent with Chan’s suggestion that people may have a lack of 
knowledge regarding smaller-scale contributors of health problems like PCPs. 
Hartmann & Klaschka’s finding regarding the important role that packaging of 
PCPs can play in consumer purchasing behavior is consistent with other studies, as a 
study by Rosette et al. regarding the role of PCP packaging suggests that consumers tend 
to believe that products labeled as “eco-friendly” are safe for use (Rosette et al., 2012). 
The suggestion from the Hartmann & Klaschka study that branding strategies like eco-
labels and terms like “natural” PCPs can sway consumers into believing that these 
products are free from toxic substances falls in line with other research studies as well. 
Aim 1C 
While data presented in Table 2 suggests that there has been a surge in mobile 
application development for assessment of PCP safety over the past 10 years, this finding 
is interesting given the example in the Hartmann & Klaschka survey that revealed how 
less than 10% of study respondents selected smartphone applications as their preferred 
information source for products (Hartmann & Klaschka, 2017). The data in Table 2 also 
indicates that while the Chemical Maze app was released in the year 2010 and has been 
around longer than some other resources, it is not as popular as other mobile applications 
that were created later on. A reason for this disparity could be that this resource costs 
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smartphone users $6.99 on the App Store and $8.49 on the Google Play store, while all of 
the other apps are free for anyone to download. 
SPECIFIC AIM 2 
Aim 2: Comparative analysis of pre-existing PCP surveys to enable development 
and modification of Mahalingaiah Lab PCP survey. 
The second component of this thesis involves the development of a 
comprehensive PCP questionnaire for the Mahalingaiah Lab. Questions regarding 
product usage frequency, estimated product application amounts, brand preferences, and 
purchasing patterns will be explored through an analysis of publicly accessible PCP 
surveys on the Internet. Because the majority of identified surveys consist of questions 
regarding general PCP usage and exposure assessments, expanding the scope of the 
Mahalingaiah Lab’s Ovulation and Menstruation (OM) Health survey to include haircare 
and skincare products in addition to cosmetics is an important aspect of this objective as 
well. 
The survey design and methodology of these external sources will be reviewed to 
help revise the Mahalingaiah Lab’s pre-existing cosmetic current survey and to better 
understand factors that may account for exposure differences to endocrine disruptors 
within the population through responses from the consumers of PCPs themselves. While 
this survey will initially be distributed via a digital platform to females between the ages 
of 18-45 currently enrolled in the Mahalingaiah Lab’s Ovulation and Menstruation (OM) 
Health Study, expanding the reach of this survey to other outlets remains of interest for 
future research endeavors. 
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METHODS AIM 2 
The development of a comprehensive PCP questionnaire involves several key 
steps (Figure 4). This process began with the compilation of any outside sources’ pre-
existing questionnaires that had similar objectives regarding PCP usage ascertainment 
and EDC exposure quantifications. Internet searches allowed for the identification of the 
majority of these PCP questionnaires, and some of these questionnaires even offered full-
text versions of questions asked publicly available online. PubMed and Google Scholar 
searches were also conducted to locate any journal articles that mentioned PCP 
questionnaires that had been employed in past research studies. The articles that were 
identified were read through to gain an understanding of the formatting, overall content, 
and specific types of questions that might be appropriate for a cross-sectional scientific 
study. When searching for these pre-existing PCP questionnaires, additional information 
on variables such as country of study was collected in order to determine applicability to 
the US population of women aged 18 to 45. 
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Figure 4. Overview of Research Methodology for PCP Questionnaire Development. 
 
After a sizeable number of surveys had been identified, the questions from these 
surveys were reviewed against those of the cosmetic survey. A comparison grid was 
generated in a Word document to keep track of the types of questions asked in (Table 3). 
All of the 18 questions from the initial questionnaire were first entered in the second 
column of the chart labeled as “OM Study: Cosmetics Module Questions”. The identified 
full-text surveys were read through, and any questions that were the same or similar to 









for Review of 
Survey Questions
Creation of Initial 






Creation of Final 




for PCP Survey 
Distribution
Submission of 














Table 3: Comparison Grid of PCP Questionnaires. 
Related Questions from Other Surveys OM Study: Cosmetics 
Module Questions 




What is your primary reason for 
wearing makeup?  
1. School  
2. Going on dates  
3. For my significant 
other  
4. Hanging with friends  
5. Work  
6. Other (please 
specify)  
  
In what situations are you most likely 
to wear makeup?  
1. Class  
2. Work  
3. Job interview  
4. Out with friends  
5. Running errands  
6. On a date  
  
What is your most preferred purpose of 
using a cosmetic product?  
1. Facial care  
2. Occupational 
requirement  
3. Young looks  
4. Improving self-
image  
5. Better feeling  
6. Medical purpose  
7. Being fashionable  
8. Attracting others   
If you do not wear makeup 
regularly (less than 
3x/week), what occasions do 
you wear makeup (select all 
that apply)?  
1. School  
2. Work  
3. Meeting up with 
friends  
4. Meeting up with 
(potential) romantic 
partners  
5. Dining out  
6. Getting drinks  
7. Parties  
8. Special occasions  
9. Other: __________  
  
Keep   N/A 
Do you remove make-up before 
sleeping? If the answer is Yes, 
please choose method:  
Yes / No  
1. with water only  
2. with make-up 
remover  
3. wet tissues  
4. water and soap  
5. other  
  
Indicate the corresponding frequency of 
use of lotion, milk, oil, foam, and wipes 
during the past 12 months (different 
types of makeup remover products)  
21. >1 time per week  
22. 1 time per week  
How do you remove 
your makeup?  
1. I don’t remove my 
makeup  
2. Wash face with just 
water   
3. Wash face with 
facial 
cleanser/soap  
4. Remove makeup 
with a non oil based 
makeup remover 
5. Remove makeup 
with an oil based 











not know if their 
makeup is oil-
based or not (e.g., 
there could be 
confusion over 
whether products 
like makeup wipes 
are oil based)   
32 
23. 1 time per month  
24. 2 or 3 times per 
month  
25. Less often  
 
Where or who do you primarily 
purchase makeup from?  
1. Department store  
2. The internet  
3. Sales rep  
4. Drug store (ex. CVS, 
Walgreens, etc.)  
5. Specialty makeup 
store (ex. Sephora, Ulta, 
etc.)  
6. Directly from 
manufacturer  
  
Where did you purchase the majority of 
your cosmetics? Is there a reason you 
selected that location?  
  
Where do you purchase cosmetics?  
1. Shopping mall  
2. Cosmetics products 
shop  
3. Nearby shop  
4. Buy online  
  
What was your preferred source of 
purchasing face creams?  
1. Supermarket  
2. Department store  
3. Medical store  
4. Cosmetic store  
5. Internet  
  
What is your most preferred place of 
purchasing a cosmetic product?  
1. Cosmetic store  
2. Pharmacy  
3. Department store  
4. Internet  
 
Where do you buy your 
makeup from (select all 
that apply)?  
1. Drugstores (e.g. 
CVS, Walgreens, 
Rite Aid)  
2. Chain retailers (e.g. 
Walmart, Target, 
Sears, Costco)  
3. Name-brand 
makeup stores (e.g. 
Sephora, Ulta)  












Do you regularly read cosmetics 
labels?  
1. Yes, and I have been 
for more than 6 months  
2. Yes, and I have been 
for less than 6 months  
3. No, but I am thinking 
about starting in the next 
30 days  
Do you buy makeup that is 
advertised as having all 
natural (organic, non-toxic, 
or toxin free) ingredients?  
1. Yes, I only buy 
makeup with all 
natural ingredients  
Keep Put this question 







4. No, but I am thinking 
about starting in the next 
6 months  
5. No, and I do not 
intend to regularly read 
cosmetics labels  
  
Do you feel you have to know about the 
composition of skin care products prior 
to using them?  
1. Yes  
2. No  
  
Are you more inclined to use skin care 
products with natural or organic 
ingredients, even if they are much 
higher than the common ones in price?  
1. Yes  
2. No  
 
2. Sometimes I buy 
makeup with all 
natural ingredients  
3. No, I don’t buy 
makeup with all 
natural ingredients  
 
 
Decisions regarding whether to add, delete, or modify the original eighteen 
questions were made in column 3 of the table, and any justifications for these decisions 
were recorded in column 4 of the table. The completed comparison grid was analyzed for 
readability using an online English language readability tool. An initial draft of the 
questionnaire was then written and shared with the principal investigator (PI) of the 
research study and other members of the Mahalingaiah Lab for their feedback. 
Modifications to the language used in the survey were made by the rewording of certain 
questions to make sure they were comprehensible and readable to respondents. The 
survey draft was finalized, and a recruitment plan was devised to pilot test the survey for 
usability.  
A draft of the survey will be submitted through Harvard’s Quality Improvement 
Program (QIP) for approval. Once the reviewers make any necessary changes, the final 
draft of the survey will be submitted as part of a research study through the Electronic 
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Submission, Tracking, & Reporting (ESTR) platform for Institutional Review Board 
(IRB) approval through Harvard Longwood Campus (HLC). Once the project receives 
IRB approval, the building of the survey in Harvard’s Research Electronic Data Capture 
(REDCap) software system can begin so that electronic distribution to participants can be 
made possible. Access to REDCap involved first applying for Person of Interest (POI) 
status through Harvard and completing initial trainings in survey building before any 
actual programming of the survey could begin. The initial trainings involved watching 
three video modules (Brief Overview, Detailed Overview, and Data Entry Overview).  
RESULTS AIM 2 
A total of 29 questionnaires about cosmetics or general PCP usage were identified 
through web searches and included in analysis. A breakdown of survey origin by country 
shows how the majority of surveys came from the US (Figure 5). Full-text versions of 18 
of the 29 surveys were available to read through entirely for inclusion in the comparison 
grid created to analyze survey question types. Reviewing each of these surveys helped to 




Figure 5. Distribution of Pre-existing PCP Questionnaires by Country of Origin. 
 
Modifications made to the survey included the revision/rewording of questions, 
the addition of entirely new questions, and the inclusion of follow-up questions to pre-
existing questions. Changes were also made to the survey flow and formatting so that 
some of the original 18 questions were moved to a different section of the survey. 
Additional questions about a respondent’s background, including questions pertaining to 
details like zip code, employment status, and the number of people living in household, 
were added to the first section of the survey based on the studies outlined in the 
introduction that highlight the various demographic factors contributing to endocrine 
dysfunction. One particular demographic variable deemed worthwhile for inclusion in the 
survey redesign was occupation, as past studies have highlighted how certain professions 
influence a respondent’s awareness of the dangers of certain products and/or heighten his 
or her susceptibility to exposure. In the background section of the survey, questions 
regarding skin type, history of skin conditions like acne and psoriasis were added to the 
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survey based on the assumption that certain skin conditions would influence a woman’s 
usage frequency of certain cosmetic and skincare products. Questions that dealt with the 
main motivation for buying a certain personal care product - whether it be the cost, 
convenience, advertisement, or a recommendation by friend - were also added under the 
section pertaining to one’s motivation for PCP usage. 
Aside from the addition of questions to the survey, changes were made to 
questions deemed incomplete to better facilitate data analysis. Survey question 17, “Have 
you ever tried changing the makeup products you use because you were concerned about 
their chemical additives?” of the cosmetic questionnaire was modified by including a 
follow-up question for respondents who select “yes” to further elaborate on what specific 
initiatives were taken to lessen their individual exposure risk. The follow-up question 
asks these respondents to select all of the ways in which they have tried changing the 
PCPs they use as a result of their potential concerns. Answer choices for respondents to 
select from include the following: researching other brands that prioritize cleaner 
ingredients, purchasing safer PCPs and implementing them into daily routine, and 
throwing away/stop using products that might cause concern due to chemical additives.  
The final draft of the survey resulted in 134 questions viewable in the appendix of 
this thesis (Appendix A). These 134 questions were broken down into the following 12 
categories: 1) Respondent Demographics, 2) Background, 3) Frequency of Use for 
Makeup, 4) Exposure for Makeup, 5) Frequency of Use for Skincare Products, 6) 
Exposure for Skincare Products, 7) Frequency of Use for Haircare Products, 8) Exposure 
for Haircare Products, 9) Motivation for PCP Usage, 10) Purchasing Preferences for 
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PCPs, 11) PCP Safety and Knowledge, and 12) Survey Conclusion. POI status to access 
the REDCap system at Harvard was filed for and subsequently approved, but the survey 
has not yet been built in the software platform due to COVID-19 related delays in IRB 
approval. 
DISCUSSION AIM 2 
The benefit of the restructuring and remodeling of the OM Health Survey is that 
the revision enables more information regarding PCP usage and exposures to be 
understood. With the inclusion of sections for skincare and haircare products, additional 
qualitative and quantitative data regarding factors like how frequently people use certain 
products, which brands they tend to gravitate towards, and how much of a product is used 
in a typical application period can be compiled so that researchers can better characterize 
the relationship between PCP-related exposures and endocrine dysfunction. Additionally, 
the decision to use an online platform to eventually distribute the survey will help to 
control for potential response bias that might come from administering the PCP survey in 
person or having researchers asking the participants questions over the phone. Because 
respondents would be in the privacy of their own homes, they might be more inclined to 
answer honestly and not just provide answers that they believe make them look/sound 
favorable in front of the researcher/over the phone. 
A limitation of the decision to expand the survey size is that its updated length 
could prevent respondents from finishing the survey in its entirety. Going from an 18-
question online survey to a 134-question survey requires respondents to dedicate more 
time and effort into its completion, which could potentially lower the response rate and 
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limit the amount of usable data for analysis. One option to limit this problem could 
involve providing compensation for participants that complete the questionnaire in its 
entirety. 
Future directions for this aspect of the analysis plan include submitting the survey 
to Harvard for IRB approval, programming the survey into REDCap, and distributing it 
to participants with the goal of receiving 25 responses. Recruitment of female 
participants to complete the survey will be targeted through social media outlets such as 
Facebook and Twitter, where there are pages dedicated to beauty products with active 
users who might be willing to assist and groups for fulfilling and completing surveys of 
others in academia. 
SPECIFIC AIMS 3A AND 3B 
Aim 3A: Assessment of patterns of geographical variation in endocrine disruptor 
exposure across the US through urinary samples collected through an existing study 
protocol. 
The third component of this thesis involves an analysis of geographic 
variances that play a role in exposure to EDCs across the US. Sociodemographic 
variables such as age, race/ethnicity, SES, and occupation have been well classified in 
influencing one’s susceptibility to EDC-related health defects, but a novel look 
at geographic differences in exposure to common chemical toxicants on a regional or 
statewide level has not yet been undertaken using the dataset analyzed for this component 
of the research project. 
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The data that will be used in this exposure assessment was collected between 
February 2017-December 2018 in a study conducted by researchers at Silent Spring 
Institute, a nonprofit research organization based in Newton, MA. This mixed-methods, 
cross-sectional study involved the assessment of urinary metabolite concentrations of 10 
common EDCs from a cohort of 726 (377 female, 182 male) participants who: 1) 
provided morning and nighttime urine samples in a urine collection kit called the “Detox 
Me Action Kit” and 2) completed an optional online questionnaire assessing their typical 
PCP usage habits. After the collection period, samples were sent one of three analytical 
laboratories (NSF International, SGS AXYS Analytical, and NSF International) where 
they were assayed for the following 10 commonly found EDCs: BPA, bisphenol S (BPS), 
BP3, TCS, TCC, 2,4-DCP, 2,5 dichlorophenol (2,5-DCP), BP, EP, and MP. Dodson et al. 
(2020)’s publication and the website https://wwww.silentspring.org/detoxmeactionkit/ 
provide further information regarding the specific details of this biomonitoring study 
(Dodson et al., 2020). To expand upon the work of Silent Spring, biological specimen 
data from the participants in this study will be evaluated in relation to relative levels of 
these toxicants within the general US population to explore the question of whether there 
exists any geographical significance in exposure differences for any of the 10 chemicals.  
Aim 3B: Creation of chemical library of toxicants and application of library 
towards menstrual effluent samples collected through an existing study protocol. 
The final component of this thesis involves the creation of a library of common 
chemical toxicants from the environment and from PCPs, many of which have 
carcinogenic or endocrine disrupting properties. Generation of the library of chemical 
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toxicants requires time to be spent identifying with potential endocrine disrupting 
abilities from three primary outlets: NHANES biomonitoring data on environmental 
chemicals, scientific publications on chemicals found in PCPs, and online resources of 
chemicals with known EDC-associated mechanistic effects. This library will then be 
applied to an existing protocol to screen for toxicants found in menstrual effluent samples 
from a pilot study of women at Icahn School of Medicine at Mount Sinai. These bioassay 
results will be used to help determine whether the menstrual blood serves as a conclusive 
test for toxicant exposure by providing quantitative data regarding both the presence and 
relative concentrations of potential EDCs. 
METHODS AIMS 3A AND 3B 
Aim 3A 
With an overarching goal of determining whether there exist geographical 
differences in the relative amounts of the 10 chemicals assayed in the Detox Me Action 
Kit on a statewide or regional scale, the research process began by looking for similar 
trends in pre-existing literature in PubMed and Google Scholar. Journal articles were 
selected using many of the same keywords as previous literature searches had already 
done (“endocrine disruptor,” “personal care products”), but descriptors such as 
“statewide,” “urban,” and “rural” “northeast,” “climate” were also included in the search 
terms for this particular instance. 
         The data was planned to be shared by the team at Silent Spring via email on an 
Excel spreadsheet after IRB approval of the project. The dataset would then be read into a 
library using SAS macro functions and Python for further analysis, where it would then 
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be used to generate several tables and figures, including a map of the 10 chemicals tested 
for using a Geographic Information System (GIS) software program that would be 
included as a figure in this paper. 
Aim 3B 
 The methodology associated with Aim 3B can be summarized in three main steps: 
the creation of a library of chemicals with potentially toxic effects towards human health, 
the generation of a word cloud of EDCs present within the generated library of chemical 
names, and involvement in a novel bioassay project screening for toxicants detectable in 
menstrual effluent samples. Participation in this biomonitoring assessment will involve 
contributing in the analysis of preliminary data generated from the screening of samples 
and applying the PCP Chemical Library towards the samples for further confirmation of 
their presence within menstrual blood (Figure 6). 
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Figure 6. Overview of Research Methodology for Menstrual Effluent Sample Analysis. 
 
Names included in the PCP Chemical Library were pulled from three main 
outlets: NHANES biomonitoring data, published scientific literature on EDCs found in 
PCPs, and Internet resources on chemicals known to have endocrine disrupting effects 
(Figure 5). The first chemicals added to the library included environmental chemicals that 
have been tested in the urine and peripheral blood using NHANES biomonitoring data 
available online up through the 2017-2018 collection year (Centers for Disease Control 
and Prevention, 2019). Additional chemicals were added to the library by taking into 
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account journal articles that highlight specific chemicals present in PCPs. The literature 
review conducted in Aim 1A of this thesis was consulted to review any bioassays that 
had linked EDC exposure to PCP usage specifically, and the metabolites measured in 
those particular studies were then added to the spreadsheet if not already listed. Toxicants 
commonly found in cosmetics, skincare, and haircare/hair dye products were also 
identified through follow up searches on PubMed and Google Scholar, where studies 
linking haircare, skincare, and cosmetic products to endocrine disruption were again 
identified and explored. Lastly, web searches on EDCs were conducted to ensure any 
additional toxicants relevant in building the library would be included at the culmination 
of chemical compilation.  
To compile the library in one centralized location, each chemical name was 
transferred to an Excel spreadsheet with its associated International Union of Pure and 
Applied Chemistry (IUPAC) International Chemical Identifier (InChiI) Key and 
Chemical Abstracts Service (CAS) Registry Number (Table 4). If not provided by the 
source, the website PubChem was used to find a chemical’s respective CAS number and 
InChiI Key. Chemical classes, other names, and abbreviations for these toxicants were 







Table 4: PCP Chemical Library. 
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After finalizing the list of names for inclusion in the PCP Chemical Library, any 
chemicals linked to endocrine disruption through past studies were denoted with the letter 
“x” in an additional column entitled “Specific Metabolites Studied as EDCs” of the 
chemical library spreadsheet (Table 4). A word cloud figure was then generated to best 
visualize the prevalence of EDCs within the entire chemical library. To facilitate the 
creation of this figure, the column entitled “Chemical Name” from Table 4 was copied 
into WordArt, a free online word cloud generator. This online tool allows users to shuffle 
the order of their inputted list(s) so that certain words appear higher in priority over 
others on the list, which ultimately enables higher-ranked word to appear in larger, 
boldface text on the graphic that the algorithm generates. This feature was employed to 
shuffle the inputted list of chemical names so that chemicals from the column designated 
as EDCs would appear in larger text on the figure that was created. 
After being used in the creation of the word cloud, the chemical library was 
applied to menstrual effluent samples from a research study between the Mahalingaiah 
Lab and researchers at the Icahn School of Medicine at Mount Sinai. Menstrual blood 
assays for this project were conducted by Dr. Doug Walker, an Assistant Professor of 
Environmental Medicine and Public Health at Mount Sinai. Use of high-resolution mass 
spectrometry (MS) platforms was employed by Mount Sinai’s team to quantify relative 
concentrations of the metabolites from this chemical library within the menstrual effluent 
samples collected by study participants. 
4 healthy females between the ages of 18-35 were recruited through research 
personnel at The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell to 
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participate in this study. Participants were compensated $55 per menstrual effluent 
sample. Additional inclusion criteria for participation in the study were as follows: 
women who had regular menstrual cycles, were not pregnant or breast-feeding, did not 
use hormonal birth control or implantable contraceptives, and did not have any known 
gynecological illnesses. Participants collected their menstrual effluent samples using 
DivaCup medical-grade silicone menstrual cups (Figure 7). The menstrual cups were for 
used for 2-3 hrs on days 1-2 of participant’s menstrual cycles (Figure 8). At the time of 
collection, participants also completed a short questionnaire regarding questions 
pertaining to their use of pain relievers, ranking of their pain severity, etc.  
 





Figure 8. DivaCup Application Guide for Menstrual Effluent Sample Collection. 
 
Menstrual effluent samples from the DivaCups were transferred into 50 
mL, BPA-free sterile containers with screw-top caps by members of the Walker 
laboratory. All specimens were frozen and shipped to the Boas Center Biorepository 
(BPCP) at The Feinstein Institute for Medical Research in Manhasset, NY. After being 
accessioned and processed at the BCP, samples were divided to simulate a fresh vs. 
frozen collection by having one portion of whole menstrual effluent immediately frozen 
in a cryovial at -20°C for 24hrs and another portion being kept at 4°C overnight in a 
cryovial for 24hrs. After the 24hr period concluded, both samples were then frozen at -
80°C and shipped overnight (on dry ice) to the Walker laboratory. The samples were then 
placed in a -80 C freezer until metabolomic analyses were performed.  
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With an overall goal of characterizing environmental and PCP-related chemical 
biomarkers in menstrual blood and more specifically - whether determination of the toxic 
chemicals collated in the PCP Chemical Library is possible in the samples from the 
Mount Sinai study - a new list of toxicants was created using the PCP Chemical Library 
as a reference guide. The PCP Chemical Library was cross-referenced with qualitative 
and quantitative data for chemicals capable of being tested for using MS techniques at 
Mount Sinai. This spreadsheet provided data for chemical names, mass to charge ratios 
(m/z), time, chemical formulas, adduct times, chemical ID, annotation confidence score, 
annotation raw score, monoisotopic mass, number of structures, sum reference counts, 
and number of PubMed articles. For the purpose of generating a list of toxicants for 
further confirmation, however, only the five columns denoted m/z (column A), time 
(column B), chemical_ID (column H), name (column N), and InChiKey_MSReady 
(column V) from the spreadsheet were accounted for. The InChiI Keys associated with 
specific chemical names from the PCP Chemical Library were copy and pasted so that 
they could be searched for within the Mount Sinai spreadsheet of to look for matching 
outputs. Any matching entries between the chemical library and Dr. Walker’s 
spreadsheet. The finalized list of toxicants compiled for confirmation was then 
transferred to an Excel document and sent to the team of researchers at Mount Sinai. 
RESULTS AIMS 3A AND 3B 
Aim 3A 
 7 articles regarding geographical variances in EDC exposure were identified from 
literature searches, 5 of which pertained to geographic variations associated with general 
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EDC exposure (Figure 9) and 2 of which pertained to geographic variations specifically 
due to PCP usage (Figure 10). 
 




Figure 10. Published Articles on Geographical Influence on EDC Exposure due to PCPs. 
 
While the Data Usage Agreement (DUA) was designed and edited extensively, 
this project could not be completed due to logistical challenges of working with both 
Harvard and BU’s legal departments regarding approval and signing of the DUA to share 
the data and begin analysis. The final version of the DUA is included in the appendix of 
this thesis (Appendix B).  
Aim 3B 
A total of 339 environmental chemicals were first included from the CDC Report 
(Centers for Disease Control and Prevention, 2019). Analysis of the Helm paper of 
endocrine disrupting and asthma-associated chemicals in hair products led to the addition 
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of 14 more chemicals for the library (Helm et al., 2018). These included metabolites from 
the following chemical classes: 3 from cyclosiloxanes (dodecamethylcycopentasiloxane, 
decamethcyclopentasiloxane, octamethylcyclotetrasiloxane), 8 from fragrances 
(phenethyl alcohol, methyl ionone, galaxolide (HHCB), bucinal, linalool, limonene, 
hexyl cinnemal, and benzylacetate), 2 from alkyl phenols (nonylphenol diethoxylate and 
nonylphenol monoethoxylate), and 1 from phthalates (diethyl phthalate (DEP)). Hair 
products in this study were also found to contain MP, but this metabolite had already 
been included in the library from the CDC report. The Kim paper provided 8 additional 
chemicals found in PCPs for inclusion in the library: para-phenylediamine (PPD), para-
aminophenol, 4,5-diaminopyrazole, pyrimidine, resorcinol, meta-aminophenol, meta-
phenyeldiamine, and pyridine (Kim et al., 2016). 
Three Internet-based sources were consulted to ensure additional toxicants 
relevant in building the library were included at the culmination of chemical compilation. 
The first source, the Campaign for Safe Cosmetics’ Chemicals of Concern Fact Sheet, 
listed out 19 chemicals/chemical categories for inclusion in the library: 1,4-dioxane, 
benzophenone, butylated compounds, carbon black, carcinogens, coal tar, ethanolamine 
compounds (MEA, TEA, and others), formaldehyde and formaldehyde-releasing 
preservatives, hydroquinone, lead and other heavy metals, nitrosamines, octinoxate, PPD, 
parabens, phthalates, resorcinol, synthetic musks, toluene, and TCS (Campaign for Safe 
Cosmetics, 2015). While the parabens, phthalates, and benzophenones had primarily been 
added earlier on, analysis of this website still enabled addition of new toxicants for the 
library. The second source identified was a report from the Breast Cancer Prevention 
52 
Partners (BCPP) entitled Right to Know: Exposing Toxic Fragrance Chemicals in Beauty, 
Personal Care and Cleaning Products (Breast Cancer Prevention Partners, 2018). 57 
chemicals found in Table 9 (Endocrine Disruptors Found in Personal Care Products), and 
6 chemicals in Table 10 (Asthmagens Found in Personal Care Products) of the BCPP’s 
report were added to the chemical library (Breast Cancer Prevention Partners). The 
United Nations (UN) List of Identified Endocrine Disrupting Chemicals, the final web 
source used in data collection for the library, identified 45 chemical substances - many of 
which had again overlapped with names already entered into the chemical library (United 
Nations Environment Programme, 2017). The analysis of these sources eventually 
resulted in a total of 490 chemicals for inclusion in the library. From there, the EDC-
associate chemical word cloud was generated (Figure 10).  
 
Figure 11. EDC Word Cloud from PCP Chemical Library. 
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Preliminary data from the pilot analysis of menstrual blood for untargeted 
assessment of metabolic signature and toxicants demonstrated 26,839 metabolic features 
matching a total of 9, 321 metabolites detected in the menstrual blood. Efforts to cross-
reference the PCP Chemical Library of 490 chemicals with the Mount Sinai library of 
1,749 chemicals resulted in a total of 68 toxicants included for additional testing for 
further determination in the menstrual effluent samples (Table 5). Final confirmation 
results for the presence of these 68 chemicals are still pending. 
Table 5: Finalized List of Toxicants Assayed for Confirmation in Menstrual 
Blood. 
Chemical Name 
(N=86) mz Time 
Chemical ID 
(Dr. Walker) InChIKey 
Glycidamide 88.03959 22.1 CF01883 
FMAZQSYXRGRES
X-UHFFFAOYSA-N 
Cotinine 159.0917 180.5 CF00028 
UIKROCXWUNQSP
J-VIFPVBQESA-N 
NNAL 210.12392 79.8 CF00071 
OGRXKBUCZFFST
L-UHFFFAOYSA-N 
Bisphenol A 229.12225 293.1 CF00898 
IISBACLAFKSPIT-
UHFFFAOYSA-N 




4-tert-Octylphenol 205.15957 323.2 CF00787 
ISAVYTVYFVQUD
Y-UHFFFAOYSA-N 
Butyl paraben 193.0866 267.1 CF00239 
QFOHBWFCKVYLE
S-UHFFFAOYSA-N 
Ethyl paraben 165.05514 28.9 CF02732 
NUVBSKCKDOMJS
U-UHFFFAOYSA-N 
n-Propyl paraben 181.08592 95.7 CF00038 
QELSKZZBTMNZE
B-UHFFFAOYSA-N 
2,4-Dichlorophenol 160.95607 210 CF02256 
HFZWRUODUSTPE
G-UHFFFAOYSA-N 





DISCUSSION AIMS 3A AND 3B 
Aim 3A 
Unfortunately, significant limitations caused by both the COVID-19 pandemic 
and institutional policies differences prevented successful completion of this project. 
While the implementation of virtual platforms for communication was necessary for 
safety reasons, it also made correspondence between various outlets all the more 
challenging. The project timeline started off smoothly, as conversations with the team of 
researchers at Silent Spring ensued in October 2020. These discussions centered around a 
potential collaboration in analysis of urinary EDC metabolites collected from the 
participants in their biomonitoring study, and various follow-up email communications 
occurred throughout the months of November and December regarding general logistics 
of the proposed project.  
Both the team at Silent Spring and the researchers in the Mahalingaiah Lab were 
eager to complete the study before the recommended final draft of the thesis was due, but 
setbacks arose when it came time to get legal clearance for transfer of the dataset used for 
analysis. The IRB approval process was undertaken through Harvard’s Electronic 
Submission, Tracking and Reporting (ESTR) platform throughout the month of 
December to ensure the dataset could be accessed according to legal guidelines. Since the 
dataset from Silent Spring was a de-identified dataset (where any identifying information 
about participants would be withheld), a non-human subjects research IRB was created in 
the ESTR platform. An IRB online decision tool developed by HLC was employed to 
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confirm the project would indeed be classified as not human subjects research. Copies of 
the decision tool’s Response Summary were included in the IRB submission request on 
ESTR, along with the relevant Collaborative Institutional Training Initiative (CITI) 
training verification documents for study team members and the agreed upon DUA 
between Silent Spring and the Mahalingaiah Lab. Attempts to contact the IRB reviewers 
at HLC over email and by phone for status updates on the IRB application were often 
unsuccessful, however, furthering delays in approval of the data transfer needed to 
conduct this project. 
At the same time the various steps of IRB approval process were being 
completed, a document was drafted to ensure appropriate considerations were taken to 
successfully execute this project. Using an online template from Harvard Database 
Support as a guide, a proposed DUA was written in December to outline the terms and 
conditions regarding the usage and transfer of Silent Spring’s dataset. This 
DUA detailed any logistical concerns pertaining to the partnership between Silent Spring 
and the Mahalingaiah Lab, such as necessary authorship agreed upon between 
collaborators for papers involving said data and any requirements for destruction of the 
dataset upon cessation of use. After the team at Silent Spring reviewed the agreement and 
requested that any changes to be made, the DUA was modified accordingly and finalized 
to be uploaded to the website DocuSign for both parties to provide their e-signature.  
Unforeseen problems arose, however, when one of the collaborators in the 
Mahalingaiah Lab was informed that the project would likely have to go through the IRB 
approval process specific to Boston University Medical Campus, where this collaborator 
56 
maintains a teaching position as an Assistant Professor. Thus, a Research with Human 
Subjects Form was submitted to the office of Human Research Affairs at Boston Medical 
Center and Boston University Medical Campus, where it was reviewed. The office 
determined the project did not need to be submitted to the IRB because it did not involve 
human subjects, did not involve publicly available data, and did not involve Health 
Information Identifiers. Before the Mahalingaiah Lab collaborator could legally sign the 
DUA, however, it still needed to be reviewed by the legal department at Boston 
University. This delay was unanticipated by the Mahalingaiah Lab team, as it was 
assumed his POI status through Harvard was sufficient coverage for him to sign the 
document. The DUA was sent to the contracts office at Boston University, and more time 
passed before it could be reviewed by the legal team. Once they finally did get back to 
the Mahalingaiah Lab, they proposed several changes (such as creating two different 
DUAs - one specific to Harvard and another to Boston University) that weren’t feasible 
to implement given the time constraints of the thesis. After considering the logistical 
challenges associated with transfer of data for this project, the difficult decision not to 
continue additional conversations and focus on other aspects of the overall thesis had to 
be made. 
Aim 3B  
A significant aspect of this research endeavor is that it provides further insight 
into the toxic chemicals present in the menstrual effluent, which is important because the 
capability of EDCs to come in direct contact with endometrial tissue suggests increased 
susceptibility to gynecological disorders like endometriosis and infertility (Mallozzi et 
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al., 2017). This untargeted approach has not yet been published in any biomonitoring 
studies taking place in the US, but similar studies have been conducted in Spain in an 
attempt to profile these menstrual blood metabolites (Jiménez-Díaz et al., 2016; Iribarne-
Durán et al., 2020). While confirmation of the 68 toxicants in the menstrual effluent was 
unable to be completed because the results of the analysis are still pending, past studies 
have provided insight that many of those included on the finalized list (Table 5) will 
indeed be confirmed. Researchers in a Spanish exploratory study screened menstrual 
blood samples of 57 participants for the presence of 6 benzophenones and 4 parabens and 
looked for associations between sociodemographic variables and menstrual blood 
metabolites (Iribarne-Durán). They were able to detect the EDCs MP, PP, and BP-3 at the 
highest frequencies within the samples, with median concentrations of 1.41 ngl/mL, 0.63 
ng/mL, and 0.70 ng/mL, respectively (Iribarne-Durán). Based on the work of Iribarne-
Durán et al., confirmation of these metabolites from the list is highly probable. 
In the future this analysis can be strengthened by corroborating it with bioassays 
from different specimens in females, including those of the placenta, amniotic fluid, and 
breast milk. The same toxicants that were detected within the menstrual blood of the 
Mount Sinai cohort of women can be screened for in other biological media to serve as 
additional verifications for prevalent EDCs that may come from the use of PCPs. 
Additionally, expanding the size of the cohort of samples is essential for future analyses 
of profiling of menstrual blood. Because only four samples were evaluated, it is nearly 
impossible to make any substantial conclusions regarding toxicant levels traceable in the 
blood in relation to the entire population.  
58 
CONCLUSION 
This thesis sought to accomplish three aims: providing a review of public 
perception and awareness of the dangers of endocrine disruption due to PCPs (Aim 1), 
designing a novel PCP exposure assessment through survey analysis of pre-existing PCP 
surveys (Aim 2), and analyzing bioassay-based EDC exposure assessments using urinary 
and menstrual effluent specimens. A better characterization of the EDC/PCP relationship 
was indeed made possible through the literature review conducted earlier, and successful 
identification of attitudes regarding PCP-related EDC exposures among the public was 
also completed during the research year. The Mahalingaiah Lab’s cosmetic survey 
underwent thorough modification and expansion after the comparative analysis with pre-
existing survey designs and can serve as a successful indicator of PCP usage frequency 
and quantifications, brand preferences, and purchasing patterns if employed in future 
studies. While the analysis of urinary specimens was unable to be successfully 
completed, insight into how to work with different collaborators and successfully execute 
multi-institutional DUAs was gained throughout the endeavor. Lastly, knowledge 
regarding the vast number of metabolites present in menstrual effluent sample was made 
possible through analysis of preliminary results from the pilot study done with Mount 
Sinai. Despite the fact that confirmatory results regarding specific toxicants are still 
pending, analysis of similar studies done in Spain suggests that EDCs like parabens and 
benzophenones will also be detected in these samples. 
Several research ideas regarding the PCP/EDC relationship were considered 
throughout research year, but unfortunately these projects could not be fully explored and 
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executed due to the constraints from the pandemic and of this thesis timeline. One project 
that has remained in development is a pilot study designed to assess the effect of 
occupational exposure to chemical toxicants on subsequent PCP usage frequency and 
behavioral patterns. The primary objective of this study is to quantify exposure to urinary 
metabolites found in hair coloring and hair processing treatments by collecting urine 
specimens from beauticians at Bebe Spa in Brookline, MA before and after a day of them 
performing hair treatments on their clients (Figure 12). Participants in the study will fill 
out a brief questionnaire regarding specific details of their occupation (e.g., number of 
hours worked per week at the salon, number of clients seen per week, etc.) sometime 
between the time of the two collection periods to account for potential occupational EDC 
exposure risks. They will also fill out the newly redesigned PCP Questionnaire during 
this time period so that the research team can get a sense of each beautician’s own PCP 
usage patterns that could factor into their susceptibility as well. The hope is that by the 
end of the study, participants will be provided suggested methods of reducing their 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 12. Proposed Occupational EDC Exposure Research Protocol. 
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Despite preliminary conversations with the salon owner, this study has not yet 
been undertaken. A potential next step for this analysis plan would involve scheduling a 
follow-up meeting with the PI, the salon owner, and other beauticians at the salon 
regarding the logistics for this project moving forward. This research project would be a 
valuable undertaking because it would build onto existing literature regarding how one’s 
occupation can influence their susceptibility towards EDC exposure. 
The work done in this thesis project is vital for the field of public health for 
several reasons. It enables a closer look at the interplay between the discoveries that 
scientists have made so far about the role of PCP usage in EDC exposure and the general 
public’s receptiveness to these concerns, which helps to establish whether informed 
choices by consumers can be made to mitigate these risks over time. Additionally, this 
thesis highlights chemicals of concern in consumer products that females use and 
assesses current resources available for combating potential reproductive health risks. 
The work makes companies responsible for producing and manufacturing PCPs aware of 
the growing interest consumers have in safe ingredients, which may make them more 
inclined to modify their product formulas to keep their profits up (which in turn may 
lessen overall PCP-related EDC exposures for females and may lead to lower incidence 
rates of certain gynecological concerns in the future). Lastly, exploration of these dangers 
also highlights the issues with current regulations for beauty products going to market 
and how further efforts by governmental agencies like the FDA should be undertaken to 




Appendix A: Personal Care Product Questionnaire 
 
Goals: Ascertain personal care product (PCP) exposure levels for different consumers 
through a series of questions regarding frequency of use and dosage/intake amounts per 
application for makeup, skincare, and haircare products. Identify brand preferences for 
different PCPs through questions about purchasing patterns (e.g., motivation, budget, 
frequency of purchases) so that further analysis regarding the chemical 
formulas/ingredient lists of top-selling beauty products can be performed. 
  
• Respondent Demographics 




2. In what city and state were you born? 
 
3. In what country were you born? 
 
4. Which category describes you? (Select all that apply) 
a. White (German, Irish, English, Italian, Polish, French, etc.) 
b. Hispanic, Latina, or Spanish Origin (Mexican, Mexican American, 
Puerto Rican, Cuban, Salvadoran, Dominican, Colombian, etc.) 
c. Black or African American (African American, Jamaican, Haitian, 
Nigerian, Ethiopian, Somali, etc.) 
d. East Asian (Chinese, Japanese, Korean, Mongolian, Taiwanese, etc.) 
e. Southeast Asian (Burmese, Cambodia, Hmong, Indonesian, Laotian, 
Malaysian, Filipino, Thai, Vietnamese, etc.) 
f. South Asian (Asian Indian, Bangladeshi, Bhutanese, Maldivian, 
Nepalese, Pakistani, Sri Lankan, etc.) 
g. American Indian or Alaskan Native (Navajo Nation, Blackfeet Tribe, 
Mayan, Aztec, Native Village of Barrow Inuplat Traditional 
Government, Nome Eskimo Community, etc.) 
h. Middle Eastern or North African (Lebanese, Iranian, Egyptian, Syrian, 
Moroccan, Algerian, etc.) 
i. Native Hawaiian or Other Pacific Islander (Native Hawaiian, Samoan, 
Chamorro, Tongan, Fijian, Marshallese, etc.) 
j. Some other race, ethnicity, or origin 
 
5. What is the highest level of education that you have completed? 
a. 8th grade or less 
b. Some high school, but did not graduate 
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c. High school graduate or GED 
d. Some college or 2-year degree 
e. 4-year college graduate 
f. More than 4-year college degree 
 
6. What is your total annual household income before tax? 
a. Below $15,000 
b. $15,000 - $24,999 
c. $50,000 - $74,999 
d. $75,000 - $99,999 
e. $100,000 - $124,999 
f. $125,000 - $149,000 
g. $150,000 - $199,999 
h. $200,000 or more 
i. Prefer not to answer 
j. Don’t know 
 
• Background  
7. Personal care products (PCPs) are a broad term used to describe items related to 
the maintenance of one’s hygiene and appearance. They can include anything 
from skincare products like creams/lotions to cosmetics products such as mascara. 
Have you ever had an allergic reaction to a PCP? 
a. Yes 
b. No 
c. Don’t know 
 
8. Which personal care product(s) did you have an allergic reaction to? (Select all 
that apply) 
a. I have not had an allergic reaction to a personal care product 
b. Skincare product (e.g., sunscreen, lotion, moisturizer) 
c. Haircare product (e.g., shampoo, hair dye, hair gel) 
d. Eye makeup product (e.g., mascara, eyeshadow, eyeliner) 
e. Lip makeup product (e.g., lipstick, lip gloss, lip liner, lip balm) 
f. Fragrance product (e.g., perfume, body spray) 
g. Concealer/Foundation 
h. Blusher/Bronzer 
i. Other: _____ 
 
9. Allergic reactions (e.g., eye irritation, breathing problems, runny or bloody nose) 
can result from formaldehyde exposure during hair-smoothing/keratin treatments 
at a salon. Have you ever had an allergic reaction during a hair-smoothing/keratin 
treatment? 




d. Don’t know 
 






f. Don’t know 
 
11. Do you have a history of skin conditions? 
a. Yes 
b. No 
c. Don’t know 
 
12. What skin conditions have you had in the past? (Select all that apply) 






g. Other: __________ 
 
13. What skin conditions are you currently dealing with? (Select all that apply) 






g. Other: __________ 
 
14. Thinking about your face, how would you rate your acne? If your acne changes 
during your menstrual cycle, please think about the acne at its worst. 
a. None or rare acne (none to a couple of pimples) 
b. Mild acne (4 or more pimples) 
c. Moderate acne (4 or more pimples that are red and irritated) 
d. Severe acne (4 or more pimples that are red, irritated, and have pus) 
 
15. Has your acne gotten worse since COVID-19? 
a. I did not have acne to begin with, and I’m still not experiencing any 
breakouts 
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b. I did not have acne to begin with, but I’m now experiencing occasional 
breakouts 
c. I did not have acne to begin with, but I’m now experiencing frequent 
breakouts 
d. I had acne to begin with, but I’m now experiencing more frequent 
breakouts 
e. I had acne to begin with, but I’m still experiencing the same number of 
breakouts as I had before 
f. Don’t know 
 
16. Thinking about your hair in its natural state (no hair-smoothing/keratin 





e. Don’t know 
 
17. Thinking about your hair in its natural state (no permanent hair dye usage within 
the past 3 months), how would you describe your hair color? 
a. Blonde 
b. Brunette 




g. Don’t know 
 
• Frequency of Use for Makeup 
18. How often do you typically wear makeup?  
a. Never  
b. On occasions only 
c. 1-2x/month  
d. 1-2x/week  
e. 3-5x/week  
f. Daily   
 
19. How often do you wear eye makeup products (e.g., mascara, eyeshadow, 
eyeliner)?  
a. Never  
b. On occasions only 
c. 1-2x/month  
d. 1-2x/week  
e. 3-5x/week  
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f. Daily   
 
20. How often do you wear lip makeup products (e.g., lipstick, lip gloss, lip liner, lip 
balm)?  
a. Never  
b. On occasions only 
c. 1-2x/month  
d. 1-2x/week  
e. 3-5x/week  
f. Daily   
 
21. How often do you wear fragrance products (e.g., perfume, body spray)?  
a. Never  
b. On occasions only 
c. 1-2x/month  
d. 1-2x/week  
e. 3-5x/week  
f. Daily   
 
22. How often do you wear concealer/foundation?  
a. Never  
b. On occasions only 
c. 1-2x/month  
d. 1-2x/week  
e. 3-5x/week  
f. Daily   
 
23. How often do you wear blusher/bronzer?  
a. Never  
b. On occasions only 
c. 1-2x/month  
d. 1-2x/week  
e. 3-5x/week  
f. Daily   
 
24. When you wear makeup, which products do you use most frequently (min 
3x/week)?  (Select all that apply) 
a. Eye makeup products (e.g., mascara, eyeshadow, eyeliner) 
b. Lip makeup products (e.g., lipstick, lip gloss, lip liner, lip balm) 
c. Fragrance products (e.g., perfume, body spray) 
d. Concealer/Foundation 
e. Blusher/Bronzer 
f. Other: __________  
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25. When you wear makeup, how long do you keep your makeup on?   
a. 0-3 hours 
b. 3-5 hours  
c. 6-9 hours  
d. 12-15 hours  
e. 15+ hours  
 
26. How do you remove your makeup?  
a. I don’t remove my makeup  
b. Wash face with just water   
c. Wash face with facial cleanser/soap  
d. Remove makeup with a non oil-based makeup remover  
e. Remove makeup with an oil-based makeup remover   
f.  Other: __________  
 
27. How often do you touch up your makeup each day? 
a. I do not touch up my makeup each day 
b. Once a day 
c. 2-3x/day 
d. 4 or more times per day 
 
28. What type of makeup do you typically carry with you for touch-ups? 
a. Eye makeup products (e.g., mascara, eyeshadow, eyeliner) 
b. Lip makeup products (e.g., lipstick, lip gloss, lip liner, lip balm) 
c. Fragrance products (e.g., perfume, body spray) 
d. Concealer/Foundation 
e. Blusher/Bronzer 
f. Other: _____ 
 
29. How has your makeup use changed since COVID-19? 
a. My use of makeup has gone up 
b. My use of makeup has stayed the same 
c. My use of makeup has gone down 
 
• Exposure for Makeup 
30. At what age did you first start wearing makeup? 
a. I have never worn makeup 
b. 12 years old or younger 
c. 12-15 years old 
d. 16-18 years old 
e. 19-21 years old 
f. 21 years old or older 
g. Don’t remember 
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31. To which of the following areas do you apply makeup? (Select all that apply)  
a. Face (skin)   
b. Eyelids 
c. Eyelashes   
d. Eyebrows   
e. Lips 
f. Other: _____   
  
32. What type of makeup products do you apply to your face? (Select all that apply)  
a. Face primer or base  
b. Concealer 
c. Foundation 
d. Blusher  
e. Bronzer  
f. Translucent face powder (e.g., setting powder, finishing powder) 
g. Other: __________  
 
33. What type of foundation do you apply to your face? (Select all that apply) 
a. I do not apply foundation to my face 
b. Liquid foundation 
c. Powder foundation 
d. Mousse/whipped foundation 
e. Stick foundation 
f. Mineral powder 
g. Tinted moisturizer 
h. BB cream 
i. CC cream 
j. Other: ________ 
 
34. How do you typically apply this product to your face? 
a. Rub on with hands 
b. Rub on using makeup brush 
c. Rub on using makeup sponge (e.g., Beautyblender sponge, wedge 
sponge, microfiber sponge, silicone sponge) 
d. Spray on using bottle 
e. Other: _________ 
  
35. What type of makeup do you apply to your eyes? (Select all that apply)  
a. Eyeliner 
b. Mascara  
c. Eyeshadow 
d. Eyeshadow primer  
e. Other: __________  
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36. What type of eyeliner do you apply to your eyes? (Select all that apply) 
a. Pencil eyeliner (powder-based) 
b. Pencil eyeliner (wax-based) 
c. Gel/cream eyeliner 
d. Liquid eyeliner 
e. Other: ______ 
 
37. What type of eyeshadow do you apply to your eyes? (Select all that apply) 
a. Powder/pressed eyeshadow 
b. Liquid eyeshadow 
c. Cream eyeshadow 
d. Stick/crayon eyeshadow 
e. Eyeshadow pigments 
f. Other: __________ 
 
38. How do you typically apply this product to your eyes? 
a. Rub on eyelid with fingers 
b. Rub on eyelid using makeup brush 
c. Roll on eyelid using bottle 
d. Other: _________ 
  
39. Approximately how many coats/layers of this makeup product do you typically 
apply to your eyes? 
a. One single coat 
b. 2-3 coats 
c. 4 or more coats 
 
40. What type of makeup do you apply to your eyebrows? (Select all that apply)  
a. Brow powder  
b. Brow wax  
c. Brow gel  
d. Brow pencil  
e. Other: __________  
 
41. How do you typically apply this product to your eyebrows? 
a. Fill in with hands 
b. Fill in using makeup brush 
c. Fill in using wand 
d. Other: _______ 
  
42. What type of makeup do you apply to your lips? (Select all that apply)  
a. Lipstick  
b. Lip gloss 
c. Lip balm 
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d. Lip stain 
e. Lip liner 
f. Other: __________  
 
43. Approximately how many coats/layers of this makeup product do you typically 
apply to your lips? 
a. One single coat 
b. 2-3 coats 
c. 4 or more coats 
 
44.     At what age did you first start wearing fragrance products (e.g., perfume, body 
spray)? 
a. I have never worn fragrance products 
b. 12 years old or younger 
c. 12-15 years old 
d. 16-18 years old 
e. 19-21 years old 
f. 21 years old or older 
g. Don’t remember 
 
45. To which of the following areas do you apply fragrance products? (Select all that 
apply)  
a. On the wrists 
b. Base of throat 
c. Inside elbow 
d. Behind ear lobes 
e. Onto the hair 
f. Onto the clothing 
g. Other: _______ 
 
46. Approximately how many spritzes of this fragrance product do you typically 
apply on one occasion? 
a. One spritz 
b. 2-3 spritzes 
c. 4 or more spritzes 
 
47. Have you ever accidentally inhaled your fragrance products when applying them? 
a. Yes 
b. No 
c. Don’t know 
  
• Frequency of Use for Skincare Products 
48. How often do you typically use skincare products? 
a. Never  
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b. On occasions only 
c. 1-2x/month  
d. 1-2x/week  
e. 3-5x/week  
f. Daily   
 
49. How often do you use moisturizers (e.g., moisturizer, lotion, face/body oil)? 
a. Never  
b. On occasions only 
c. 1-2x/month  
d. 1-2x/week  
e. 3-5x/week  
f. Daily   
 
50. How often do you use cleansers (e.g., face/body wash, toner, exfoliators & scrubs, 
cleansing brushes)? 
a. Never  
b. On occasions only 
c. 1-2x/month  
d. 1-2x/week  
e. 3-5x/week  
f. Daily   
 
51. How often do you use facial treatments and serums (e.g., face serums, facial 
peels, face masks, acne & blemish treatments)? 
a. Never  
b. On occasions only 
c. 1-2x/month  
d. 1-2x/week  
e. 3-5x/week  
f. Daily   
 
52. How often do you use eye treatments (e.g., eye creams, eye serums, eye masks)? 
a. Never  
b. On occasions only 
c. 1-2x/month  
d. 1-2x/week  
e. 3-5x/week  
f. Daily   
 
53. How often do you use sun care products (e.g., sunscreen, self-tanner, after sun 
care)? 
a. Never  
b. On occasions only 
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c. 1-2x/month  
d. 1-2x/week  
e. 3-5x/week  
f. Daily   
 
54. When you use skincare products, which products do you use most frequently (min 
3x/week)?  (Select all that apply) 
a. Moisturizers (e.g., moisturizer, lotion, face/body oil) 
b. Cleansers (e.g., face/body wash, toner, exfoliators & scrubs, cleansing 
brushes) 
c. Facial treatments & serums (e.g., face serums, facial peels, face masks, 
acne & blemish treatments) 
d. Eye treatments (e.g., eye creams, eye serums, eye masks) 
e. Sun care products (e.g., sunscreen, self-tanner, after sun care) 
f. Other: __________  
 
55. When you use skincare products, how long do you keep them on for? 
a. I do not use skincare products 
b. 0-3 hours 
c. 3-5 hours  
d. 6-9 hours  
e. 12-15 hours  
f. 15+ hours  
 
56. If you wear sunscreen, when do you apply it? 
a. I do not wear sunscreen 
b. Year-round 
c. Seasonally (e.g., in the summertime/if the weather is warm) 
d. Other: ______ 
 
57. If you wear sunscreen, what factor/SPF value do you wear most often? 
a. I do not wear sunscreen 
b. SPF 15 
c. SPF 30 
d. SPF 50 
e. Other: ______ 
 
58. How has your skincare product usage changed since COVID-19? 
a. My use of skincare products has gone up 
b. My use of skincare products has stayed the same 
c. My use of skincare products has gone down 
 
• Exposure for Skincare Products 
59. At what age did you first start using skincare products? 
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a. I have never used skincare products 
b. 12 years old or younger 
c. 12-15 years old 
d. 16-18 years old 
e. 19-21 years old 
f. 21 years old or older 
g. Don’t remember 
 
60. To which of the following areas do you apply skincare products? (Select all that 
apply) 






61. What types of products do you apply to your face? (Select all that apply) 
a. Moisturizers (moisturizer, lotion, face oil) 
b. Cleansers (face wash, toner, exfoliators & scrubs, cleansing brushes) 
c. Facial treatments & serums (face serums, facial peels, face masks, 
sheet masks, acne & blemish treatments) 
d. Eye treatments (eye creams, eye serums, eye masks) 
e. Sun care (sunscreen, self-tanner, after sun care) 
f. Other: __________  
 
62. Approximately how many coats/layers of this skincare product do you apply to 
your face? 
a. One single coat 
b. 2-3 coats 
c. 4 or more coats 
 
63. What types of products do you apply to your arms? (Select all that apply) 
a. Moisturizers (moisturizer, lotion, body oil) 
b. Cleansers (body wash, exfoliators & scrubs, cleansing brushes) 
c. Sun care (sunscreen, self-tanner, after sun care) 
d. Other: __________  
 
64. Approximately how many coats/layers of this skincare product do you apply to 
your arms? 
a. One single coat 
b. 2-3 coats 
c. 4 or more coats 
 
65. What types of products do you apply to your legs? (Select all that apply) 
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a. Moisturizers (moisturizer, lotion, body oil) 
b. Cleansers (body wash, exfoliators & scrubs, cleansing brushes) 
c. Sun care (sunscreen, self-tanner, after sun care) 
d. Other: __________  
 
66. Approximately how many coats/layers of this skincare product do you apply to 
your legs? 
a. One single coat 
b. 2-3 coats 
c. 4 or more coats 
 
67. What types of products do you apply to your stomach? (Select all that apply) 
a. Moisturizers (moisturizer, lotion, body oil) 
b. Cleansers (body wash, exfoliators & scrubs, cleansing brushes) 
c. Sun care (sunscreen, self-tanner, after sun care) 
d. Other: __________  
 
68. Approximately how many coats/layers of this skincare product do you apply to 
your stomach? 
a. One single coat 
b. 2-3 coats 
c. 4 or more coats 
 
69. What types of products do you apply to your back? (Select all that apply) 
a. Moisturizers (moisturizer, lotion, body oil) 
b. Cleansers (body wash, exfoliators & scrubs, cleansing brushes) 
c. Sun care (sunscreen, self-tanner, after sun care) 
d. Other: __________  
 
70. Approximately how many coats/layers of this skincare product do you apply to 
your back? 
a. One single coat 
b. 2-3 coats 
c. 4 or more coats 
 
• Frequency of Use for Haircare Products 
71. How often do you typically use haircare products? 
a. Never  
b. On occasions only 
c. 1-2x/month  
d. 1-2x/week  
e. 3-5x/week  
f. Daily   
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72. When you use haircare products, which products do you use most frequently (min 
3x/week)? (Select all that apply) 
a. Shampoo 
b. Conditioner 
c. Dry Shampoo 
d. Leave-In Conditioner 
e. Hairspray 
f. Heat protectant 
g. Detangling spray 
h. Permanent hair dye 
i. Semi-permanent hair dye 
j. Temporary hair dye 
k. Hair mousse 
l. Hair gel 
m. Anti-frizz cream/polish 
n. Hot oil treatment 
o. Root stimulator 
p. Relaxer 
q. Other: _____ 
 
73. When you use haircare products, how long do you keep them on for? 
a. I do not use haircare products 
b. 0-3 hours 
c. 3-5 hours 
d. 6-9 hours 
e. 12-15 hours 
f. 15+ hours 
 
74. Have you ever used permanent hair dye (e.g., hair dye that lasts 4-6 weeks or until 
your hair grows out again)? 
a. Yes 
b. No 
c. Don’t know 
 




c. Don’t know 
 
76. How often do you color your hair with permanent hair dye using an at-home box 
kit? 
a. Never  
b. On occasions only 
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c. 1-2x/year   
d. 3-5x/year  
e. More than 5x/year 
 
77. How often do you get your hair colored with permanent hair dye at a salon? 
a. Never  
b. On occasions only 
c. 1-2x/year   
d. 3-5x/year  
e. More than 5x/year 
 
78. Have you ever gotten a hair-smoothing/keratin treatment at a salon? 
a. Yes 
b. No 
c. Don’t know 
 
79. How often do you get hair-smoothing/keratin treatments at a salon? 
a. Never  
b. On occasions only 
c. 1-2x/year   
d. 3-5x/year  
e. More than 5x/year 
 
80. When you get a hair-smoothing/keratin treatment at a salon, how long does it 
usually last? 
a. I have never gotten a hair-smoothing/keratin treatment at a salon 
b. 0-4 weeks 
c. 4-8 weeks 
d. 8-12 weeks 
e. Greater than 12 weeks 
 
81. How has your haircare product usage changed since COVID-19? 
a. My use of haircare products has gone up 
b. My use of haircare products has stayed the same 
c. My use of haircare products has gone down 
 
82. How has your use of permanent hair dyes (either from at-home box kits or salon 
visits) changed since COVID-19? 
a. My use of permanent hair dyes has gone up 
b. My use of permanent hair dyes has stayed the same 
c. My use of permanent hair dyes has gone down 
 
83. How has your use of hair-smoothing/keratin treatments changed since COVID-
19? 
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a. My use of hair-smoothing/keratin treatments has gone up 
b. My use of hair-smoothing/keratin treatments has stayed the same 
c. My use of hair-smoothing/keratin treatments has gone down 
 
• Exposure for Hair Products 
84. At what age did you first use haircare products? 
a. I have never used haircare products 
b. 12 years old or younger 
c. 12-15 years old 
d. 16-18 years old 
e. 19-21 years old 
f. 21 years old or older 
g. Don’t remember 
 
85. At what age did you first use permanent hair dye from an at-home box kit? 
a. I have never used permanent hair dye from an at-home box kit 
b. 12 years old or younger 
c. 12-15 years old 
d. 16-18 years old 
e. 19-21 years old 
f. 21 years old or older 
g. Don’t remember 
 
86. At what age did you first get your hair colored with permanent hair dye at a 
salon? 
a. I have never gotten my hair colored with permanent hair dye at a salon 
b. 12 years old or younger 
c. 12-15 years old 
d. 16-18 years old 
e. 19-21 years old 
f. 21 years old or older 
g. Don’t remember 
 
87. At what age did you first get a hair-smoothing/keratin treatment? 
a. I have never had a hair-smoothing/keratin treatment 
b. 12 years old or younger 
c. 12-15 years old 
d. 16-18 years old 
e. 19-21 years old 
f. 21 years old or older 
g. Don’t remember 
 
88. To which of the following areas do you apply haircare products? (Select all that 
apply) 
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a. Only the roots 
b. Only the ends 
c. Throughout the entire head of hair 
 
89. To which of the following areas do you apply permanent hair dye from an at-
home box kit? (Select all that apply) 
a. Only the roots 
b. Only the ends 
c. Throughout the entire head of hair 
 
90. To which of the following areas do you get permanent hair dye applied to at a 
salon? (Select all that apply) 
a. Only the roots 
b. Only the ends 
c. Throughout the entire head of hair 
 
• Motivation for PCP Usage 
91. Why do you wear makeup? (Select all that apply)  
a. It’s part of my routine  
b. I like the process of putting it on  
c. I like using it to enhance my facial features  
d. I like how it looks  
e. I’m self-conscious about my appearance  
f. I use it to even the tone of my skin  
g. I use it to cover my acne  
h. I use it to deal with oily skin  
i. I use it to deal with dry skin  
j. I use it to hide facial hair growth   
k. Other: __________  
  
92. If you do not wear makeup regularly (less than 3x/week), what occasions do you 
wear makeup? (Select all that apply)  
a. School  
b. Work  
c. Meeting up with friends  
d. Meeting up with (potential) romantic partners  
e. Dining out  
f. Getting drinks  
g. Parties  
h. Special occasions  
i. Other: __________  
 
93. Why do you use skincare products? (Select all that apply) 
a. They’re part of my routine  
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b. I like the process of putting them on  
c. I like how they make my skin look 
d. I’m self-conscious about my appearance  
e. I use them to even the tone of my skin  
f. I use them to deal with my acne  
g. I use them to deal with oily skin  
h. I use them to deal with dry skin  
i. I use them to hide facial hair growth   
j. Other: __________  
 
94. Why do you use haircare products? (Select all that apply) 
a. They’re part of my routine  
b. I like the process of putting them on  
c. I like how they make my hair look 
d. I’m self-conscious about my appearance  
e. I prefer another hair color over my natural hair color 
f. I use them to deal with grey hair 
g. I use them to deal with oily hair 
h. I use them to deal with dry hair 
i. I use them to deal with frizzy hair 
j. I use them to add volume to my hair 
k. Other: __________  
 
95. Why do you get hair smoothing/keratin treatments? (Select all that apply) 
a. They’re part of my routine  
b. I like how they make my hair look 
c. I’m self-conscious about my appearance 
d. I use them to deal with frizzy hair 
e. I use them to add shine to my hair 
f. Other: __________  
 
• Purchasing Preferences for PCPs 
96. What is the most important factor in your decision to purchase a certain personal 
care product? 






g. Other: __________ 
  
97. How often do you purchase makeup? 
a. Once a week 
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b. Once a month 
c. Once a season 
d. Once a year 
e. Only when I run out of an item 
f. Other: ______ 
 
98. How often do you purchase skincare products? 
a. Once a week 
b. Once a month 
c. Once a season 
d. Once a year 
e. Only when I run out of an item 
f. Other: ______ 
 
99. How often do you purchase haircare products? 
a. Once a week 
b. Once a month 
c. Once a season 
d. Once a year 
e. Only when I run out of an item 
f. Other: ______ 
 
100. How much do you typically spend on a single makeup product? 




e. More than $50 
 
101. How much do you typically spend on a single skincare product? 




e. More than $50 
 
102. How much do you typically spend on a single haircare product? 




e. More than $50 
 
103. How much do you typically spend on an at-home box kit of permanent hair dye? 
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e. More than $50 
 
104. How much do you typically spend on a permanent hair dye treatment at a salon? 




e. More than $250 
 
105. How much do you typically spend on a hair-smoothing/keratin treatment at a 
salon? 




e. More than $250 
 
106. What types of makeup products do you buy most often? 
a. Eye makeup products (e.g., mascara, eyeshadow, eyeliner) 
b. Lip makeup products (e.g., lipstick, lip gloss, lip liner, lip balm) 
c. Fragrance products (e.g., perfume, body spray) 
d. Concealer/Foundation 
e. Blusher/Bronzer 
f. Other: _____ 
 
107.  What types of skincare products do you buy most often? 
a. Moisturizers (moisturizer, night cream, face/body oil) 
b. Cleansers (face/body wash, toner, exfoliators & scrubs, cleansing brushes) 
c. Facial treatments & serums (face serums, facial peels, face masks, sheet 
masks, acne & blemish treatments) 
d. Eye treatments (eye creams, eye serums, eye masks) 
e. Sun care (sunscreen, self-tanner, after sun care) 
f. Other: __________  
 
108. What types of haircare products do you buy most often? 
a. Shampoo 
b. Conditioner 
c. Dry Shampoo 
d. Leave-In Conditioner 
e. Hairspray 
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f. Heat protectant 
g. Detangling spray 
h. Permanent hair dye 
i. Semi-permanent hair dye 
j. Temporary hair dye 
k. Hair mousse 
l. Hair gel 
m. Anti-frizz cream/polish 
n. Hot oil treatment 
o. Root stimulator 
p. Relaxer 
q. Other: _____ 
 





e. Estee Lauder 
f. Smashbox 
g. Bare Minerals 
h. NARS 
i. Bobbi Brown 
j. MAC 
k. Glossier 
l. Other: _______ 
 
110. What brands of skincare products do you buy most often? 
a. Aveeno 
b. Neutrogena 








k. Mario Badescu 
l. Other: _______ 
 
111. What brands of haircare products do you buy most often? (Select all that apply) 




d. Herbal Essences 
e. Garnier 





k. Nice ‘N Easy 
l. Other: _______ 
 
112. Where do you buy your personal care products from? (Select all that apply)  
a. Drugstores (e.g., CVS, Walgreens, Rite Aid)  
b. Chain retailers (e.g., Walmart, Target, Sears, Costco)  
c. Name-brand makeup stores (e.g., Sephora, Ulta)  
d. Natural makeup stores (e.g., Pacifica, Lush Cosmetics, Mineral Fusion) 
e. Directly from a salon  
f. Online (e.g., Amazon)  
g. Other: __________  
  
113. Do you use tester products before purchasing personal care products? 
a. Yes, I always use tester products before purchasing personal care products 
b. Sometimes I use tester products before purchasing personal care products 
c. No, I don’t use tester products before purchasing personal care products 
 
114. Do you buy personal care products that are advertised as having all natural (organic, 
non-toxic or toxin free) ingredients?  
a. Yes, I only buy personal care products with all-natural ingredients  
b. Sometimes I buy personal care products with all-natural ingredients  
c. No, I don’t buy personal care products with all-natural ingredients  
d. Don’t know 
  
115. Do you buy makeup that is advertised as paraben- or phthalate-free?  
a. Yes, I only buy makeup that is paraben- and phthalate-free  
b. Sometimes I buy makeup that is paraben- and phthalate-free  
c. No, I don’t buy makeup that is paraben- and phthalate-free  
d. Don’t know  
 
116. Do you buy sunscreen that is advertised as oxybenzone-free? 
a. Yes, I only buy sunscreen that is oxybenzone-free 
b. Sometimes I buy sunscreen that is oxybenzone-free 
c. No, I don’t buy sunscreen that is oxybenzone-free 
d. Don’t know 
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117. Do you buy at-home box kits of permanent hair dye that are advertised as ammonia- 
and paraphenylenediamine (PPD)-free? 
a. Yes, I only buy at-home box kits that are ammonia- and PPD-free 
b. Sometimes I buy at-home box kits that are ammonia- and PPD-free 
c. No, I don’t buy at-home box kits that are ammonia- and PPD-free 
d. Don’t know 
   
• PCP Safety and Knowledge 











120. Do you clean your makeup applicators (e.g., brushes, sponges) regularly? 
a. Yes, I clean my makeup applicators approximately every 7-10 days 
b. No, I do not clean my makeup applicators regularly 
 
121. Do you ever share and/or borrow makeup? 
a. Yes, I share makeup with others and borrow makeup from them 
b. I share makeup with others but do not borrow makeup 
c. I borrow makeup from others but do not share makeup 
d. No, I never share or borrow makeup 
 
122. Where do you learn about different personal care products?  
a. Social media (e.g., Facebook, Instagram, Snapchat, Twitter)  
b. Makeup websites   
c. TV advertisements  
d. Magazines  
e. YouTube  
f. I don’t do research on makeup products before using them 
g. Other: _______ 
 
123. Do you want to learn more about what makes a personal care product safe?  
a. Yes   
b. No  
c. Don’t care  
  
124. Are you concerned about the health effects of personal care products?  
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a. Yes  
b. No   
 
125. Do you regularly read labels before purchasing personal care products?  




126. Do any of your makeup products (e.g., oils, lipsticks) contain UV filters, even though 
they are not marketed as sun protectants? 
a. Yes 
b. No 
c. Don’t know 
 
127. Do any of your makeup products contain parabens or phthalates? 
a. Yes 
b. No 
c. Don’t know 
 
128. Do any of your sunscreen products contain oxybenzones? 
a. Yes 
b. No 
c. Don’t know 
 




c. Don’t know 
  
130. Have you ever tried changing the personal care products you use because you were 
concerned about their chemical additives?  
a. Yes  
b. No  
 
131. How have you tried changing the personal care products you use as a result of your 
concerns? (Select all that apply) 
a. I am not concerned about the personal care products I use 
b. I have researched other brands that prioritize cleaner ingredients 
c. I have purchased safer personal care products and implemented them into 
my daily routine 
d. I have thrown away or stopped using products that might cause concern 
because of their chemical additives 
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132. Are you aware of any of the following resources to verify the safety of ingredients in 
personal care products and/or promote clean beauty practices? (Select all that apply) 
a. I am not currently aware of any resources available to the public that do 
this 
b. Smartphone Applications (e.g., Think Dirty, CosmEthics, Detox Me) 
c. Websites (e.g., EWG SkinDeep Cosmetics Database) 
d. Packaging Labels (e.g., MADE SAFE, USDA Organic) 
e. Conscious Retailers (e.g., Follain, Acure, Ilia Beauty) 
f. Other: _________ 
 
• Survey Conclusion 




134. How would you like to keep up with the study and hear about the results? (Select all 
that apply) 
a. Study website 



























Appendix B: Data Usage Agreement 
 
This data usage agreement (“Agreement”) is entered into between Dr. 
Shruthi Mahalingaiah (“Recipient”) and Silent Spring Institute (“Provider”) governing 
the use of the materials (“Data Set”) to be analyzed.   
  
The purpose of this Agreement is to provide Recipient with access to a Limited Data Set 
(“LDS”) for use in the following titled research project: Geographic Distribution of 
Exposure to Ten Common Endocrine Disrupting Chemicals in Consumer Personal Care 
Products under the direct supervision of Dr. Shruthi Mahalingaiah in accord with the 
HIPAA Regulations.  
  
I. Acceptance of this Agreement  
  
By analyzing or otherwise accessing the Materials, Recipient represents his/her 
acceptance of the terms of this Agreement.  
  
II. Modification of this Agreement  
  
Providers may modify the terms of this Agreement at any time. However, any 
modifications to this Agreement will only be effective for datasets subsequent to such 
modification. No modifications will supersede any previous terms that were in effect at 
the time of Recipient’s access.  
  
III. Use of the Materials  
  
Use of the Materials include but are not limited to viewing parts or the whole of the 
content included in the Materials; comparing data or content from the Materials with data 
or content in other Materials; verifying research results with the content included in the 
Materials; and extracting and/or appropriating any part of the content included in the 
Materials for the purposes detailed in Sections XI, XII and XIII below.   
  
In Use of the Materials, Recipient represents that:  
  
1. Recipient is not bound by any pre-existing legal obligations or other 
applicable laws that prevent Recipient from analyzing or using the Materials;  
2. Recipient will not use the Materials in any way prohibited by applicable 
laws;  
3. Recipient has no knowledge of and will therefore not be responsible for 
any restrictions regarding the use of Materials beyond what is described in this 
Agreement; and  
4. Recipient has no knowledge of and will therefore not be responsible for 
any inaccuracies and any other such problems with regards to the content of 
the Materials and the accompanying citation information.  
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In his/her Use of the Materials, Recipients cannot:  
  
1. obtain information from the Materials that results in Recipient or any third 
party(ies) directly or indirectly identifying any research subjects with the aid 
of other information acquired elsewhere;  
2. produce connections or links among the information included in 
Provider’s datasets (including information in the Materials), or between the 
information included in Provider’s datasets (including information in the 
Materials) and other third-party information that could be used to identify any 
individuals or organizations, not limited to research subjects; and  
3. extract information from the Materials that could aid Recipient in gaining 
knowledge about or obtaining any means of contacting any subjects already 
known to Recipient.  
  
IV. Representations and Warranties  
  
PROVIDER REPRESENTS THAT PROVIDER HAS ALL RIGHTS REQUIRED TO 
MAKE AVAILABLE AND DISTRIBUTE THE MATERIALS. EXCEPT FOR SUCH 
REPRESENTATION, THE MATERIALS IS PROVIDED “AS IS” AND “AS 
AVAILABLE” AND WITHOUT WARRANTY OF ANY KIND, EXPRESS OR 
IMPLIED, INCLUDING, BUT NOT LIMITED TO, NON-INFRINGEMENT, 
MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, AND ANY 
WARRANTIES IMPLIED BY ANY COURSE OF PERFORMANCE OR USAGE OF 
TRADE, ALL OF WHICH ARE EXPRESSLY DISCLAIMED.  
  
WITHOUT LIMITING THE FOREGOING, PROVIDER DOES NOT WARRANT 
THAT: (A) THE MATERIALS ARE ACCURATE, COMPLETE, RELIABLE OR 
CORRECT; (B) THE MATERIALS FILES WILL BE SECURE; (C) THE MATERIALS 
WILL BE AVAILABLE AT ANY PARTICULAR TIME OR LOCATION; (D) ANY 
DEFECTS OR ERRORS WILL BE CORRECTED; (E) THE MATERIALS AND 
ACCOMPANYING FILES ARE FREE OF VIRUSES OR OTHER HARMFUL 
COMPONENTS; OR (F) THE RESULTS OF USING THE MATERIALS WILL MEET 
RECIPIENT’S REQUIREMENTS. RECIPIENT’S USE OF THE MATERIALS IS 
SOLELY AT RECIPIENT’S OWN RISK.  
  
V. Limitation of Liability  
  
IN NO EVENT SHALL PROVIDER BE LIABLE UNDER CONTRACT, TORT, 
STRICT LIABILITY, NEGLIGENCE OR ANY OTHER LEGAL THEORY WITH 
RESPECT TO THE MATERIALS (I) FOR ANY DIRECT DAMAGES, OR (II) FOR 
ANY LOST PROFITS OR SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE, OR 
CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER.  
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VI. Indemnification  
  
Recipient will indemnify and hold Provider harmless from and against any and all loss, 
cost, expense, liability, or damage, including, without limitation, all reasonable attorneys’ 
fees and court costs, arising from the i) Recipient’s misuse of the Materials; (ii) 
Recipient’s violation of the terms of this Agreement; or (iii) infringement by Recipient or 
any third party of any intellectual property or other right of any person or entity contained 
in the Materials. Such losses, costs, expenses, damages, or liabilities shall include, 
without limitation, all actual, general, special, and consequential damages.  
  
VII. Dispute Resolution  
  
Recipient and Provider agree that any cause of action arising out of or related to the 
analysis or use of the Materials must commence within one (1) year after the cause of 
action arose; otherwise, such cause of action is permanently barred.  
  
This Agreement shall be governed by and interpreted in accordance with the laws of the 
Commonwealth of Massachusetts (excluding the conflict of laws rules thereof). All 
disputes under this Agreement will be resolved in the applicable state or federal courts of 
Massachusetts. Recipient consents to the jurisdiction of such courts and waives any 
jurisdictional or venue defenses otherwise available.  
  
VIII. Integration and Severability  
  
This Agreement represents the entire agreement between Recipient and Provider with 
respect to the analyzing and use of the Materials, and supersedes all prior or 
contemporaneous communications and proposals (whether oral, written or electronic) 
between Recipient and Provider with respect to analyzing or using the Materials. If any 
provision of this Agreement is found to be unenforceable or invalid, that provision will 
be limited or eliminated to the minimum extent necessary so that the Agreement will 
otherwise remain in full force and effect and enforceable.  
  
IX. Miscellaneous  
  
Provider may assign, transfer or delegate any of its rights and obligations hereunder 
without consent. No agency, partnership, joint venture, or employment relationship is 
created as a result of the Agreement and neither party has any authority of any kind to 
bind the other in any respect outside of the terms described within this Agreement. In any 
action or proceeding to enforce rights under the Agreement, the prevailing party will be 
entitled to recover costs and attorneys’ fees.  
  
X. Access to Data  
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Names of Recipient’s team having access to dataset from the Mahalingaiah Lab at 
Harvard School of Public Health include: Megan FitzPatrick and Shruthi Mahalingaiah. 
Names of Provider’s team involved in the sharing of the dataset include: Robin Dodson 
and Ruthann Rudel.  
  
XI. Ownership and Sharing of Data  
  
Provider will maintain ownership and control of the data at all times. Recipient will use 
dataset only for intended purpose as outlined in this agreement. Dataset will be used in 
manuscript that will be submitted for master’s thesis on behalf of Recipient (Megan 
FitzPatrick) for Boston University School of Medicine, Division of Graduate Medical 
Sciences in April 2021. Recipient agrees that any journal publication involving material 
from dataset will not be submitted for review until Summer 2021. Recipient agrees that 
nothing involving material from dataset will go out for review by any third party until 
Provider’s manuscript (“Influence of living in the same home on biomonitored levels of 
consumer product chemicals”) currently undergoing review is published. Recipient 
agrees to destroy dataset upon journal publication involving material from dataset.  
  
XII. Authorship  
  
Provider will have right to review and make recommendations regarding the suitability of 
any analyses from this dataset for inclusion in a manuscript submission to a peer-
reviewed journal or other third-party venue. After agreement by Provider and Recipient 
regarding the suitability of analyses for publication, the Provider will be given the 
opportunity to make revisions and recommendations to the subsequently prepared 
manuscript. For any publications involving analysis of material from this dataset, Megan 
FitzPatrick and Shruthi Mahalingaiah will be dual first-authors if permitted by journal. If 
not, Megan will be first position and Shruthi will be second position. Robin Dodson will 
be third author. Ruthann Rudel will be last author. Additional members from Provider’s 
team will be on it as they see fit.  
  
XIII. Study Summary  
  
The study “Geographic Distribution of Exposure to Ten Common Endocrine Disrupting 
Chemicals in Consumer Personal Care Products” conducted by Recipient will involve 
looking at the geographic distribution of exposure to ten common endocrine disrupting 
chemicals assayed in the Detox Me Action Kit. Recipient will analyze whether different 
U.S. states have different markers for use by assessing exposure levels to these different 
chemicals statewide and will incorporate findings into tables and figures for a manuscript 
regarding chemical biomonitoring in personal care products.  
  
The data requested by Recipient is a de-identified human subject dataset from 
participants who participated in the Detox Me Action Kit. Only participants that have 
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consented to have their data shared with other researchers will have their data be used, 
and all IDs will be masked by Provider before being shared with Recipient.   
  
Recipient will handle all paperwork related to IRB approval for this study, including 
submission of the Not Human Subjects Research Determination Request letter and 
submission of accompanying Data Usage Agreement into Harvard ESTR for study 
approval.  
  
Provider will share dataset by exporting it onto Excel spreadsheet/CSV file and emailing 
it to Recipient. Recipient will read dataset into library using SAS macro functions or 
Python to analyze the data. Recipient will use dataset to generate tables and figures, 
including a map of the ten chemicals tested for using a Geographic Information System 
(GIS Software). Manuscript will be circulated for publication in Summer 2021. Recipient 
agrees to destroy dataset upon publication of manuscript and will confirm destruction of 
the dataset with the Provider via email.  
  
XIV. Signatures  
  
  
______________________________                                   ________________________




______________________________                                  ________________________




______________________________                                   ________________________  




______________________________                                            ________________________ 
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